


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 285/24, 417/04, 417/12, 453/02, 453/06, A61K 31/54</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/49692 (43) International Publication Date: 31 December 1997 (31.12.97)</p>
<p>(21) International Application Number: PCT/DK97/00266 (22) International Filing Date: 19 June 1997 (19.06.97) (30) Priority Data: 0693/96 21 June 1996 (21.06.96) DK 1451/96 19 December 1996 (19.12.96) DK (71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK). (72) Inventors: PIROTTE, Bernard; 5, rue Tollet, B-4680 Oupeye (BE). LEBRUN, Philippe; 102, rue des Chats, B-1082 Bruxelles (BE). De TULLIO, Pascal; 31, rue sur les Moulins, B-4020 Liège (BE). SOMERS, Fabian; 109, rue Lairesse, B-4020 Liège (BE). DELARGE, Jacques; 7, rue Haie des Chênes, B-4140 Dolembreux (BE). HANSEN, John, Bondo; Langåsen 3, DK-4450 Jyderup (DK). NIELSEN, Flemming, Elmelund; Furesø Parkvej 46, DK-2830 Virum (DK). HANSEN, Holger, Claus; Annexgårdsparken 43, DK-3500 Værløse (DK). MOGENSEN, John, Patrick; Dybendalsvej 69, DK-2720 Vanløse (DK). TAGMOSE, Tina, Møller; Farum Hovedgade 52, 204, DK-3520 Farum (DK).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>

(54) Title: 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE



(57) Abstract

1,2,4-Benzothiadiazine derivatives represented by formula (I) wherein D, R¹, R², R³, R⁴, R⁵, R¹², R¹³, R¹⁴, R¹⁵ are defined in the description, compositions thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

1,2,4-Benzothiadiazine Derivatives, their Preparation and Use

FIELD OF THE INVENTION

5 The present invention relates to 1,2,4-benzothiadiazine derivatives, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy e.g. in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

10

BACKGROUND OF THE INVENTION

Potassium channels play an important role in membrane potential. Among the different types of potassium channels are the ATP-sensitive (K_{ATP} -) channels which are regulated
15 by changes in the intracellular concentration of adenosine triphosphate. The K_{ATP} -channels have been found in cells from various tissues such as cardiac cells, pancreatic cells, skeletal muscles, smooth muscles, central neurons and adenohypophysis cells. The channels have been associated with diverse cellular functions for example hormone secretion (insulin from pancreatic beta-cells, growth hormone and prolactin from adeno-
20 hypophysis cells), vasodilation (in smooth muscle cells), cardiac action potential duration, neurotransmitter release in the central nervous system.

Modulators of the K_{ATP} -channels have been found to be of importance for the treatment of various diseases. Certain sulphonylureas which have been used for the treatment of non-
25 insulin-dependent diabetes mellitus act by stimulating insulin release through an inhibition of the K_{ATP} -channels on pancreatic beta-cells.

The potassium channel openers, which comprise a heterogeneous group of compounds, have been found to be able to relax vascular smooth muscles and have therefore been
30 used for the treatment of hypertension.

In addition, potassium channel openers can be used as bronchodilators in the treatment of asthma and various other diseases.

Furthermore, potassium channel openers have been shown to promote hairgrowth, and have been used for the treatment of baldness.

5 Potassium channel openers are also able to relax urinary bladder smooth muscle and therefore, can be used for the treatment of urinary incontinence. Potassium channel openers which relax smooth muscle of the uterus can be used for treatment of premature labor.

By acting on potassium channels of the central nervous system these compounds can be
10 used for treatment of various neurological and psychiatric diseases such as Alzheimer, epilepsy and cerebral ischemia.

Further, the compounds are found to be useful in the treatment of benign prostatic hyperplasia, erectile dysfunction and in contraception.

15

Compounds of the present invention, which inhibit insulin secretion by activating potassium channels of the beta-cell can be used in combination with compounds which reduce blood glucose levels. Examples of such compounds are insulin, insulin sensitizers, such as thiazolidinediones, insulin secretagogues, such as repaglinide,
20 tolbutamide, glibenclamide and glucagon like peptide (GLP1), inhibitors of α -glucosidases and hepatic enzymes responsible for the biosynthesis of glucose, and glucagon.

Recently, it has been shown that Diazoxide (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine
25 1,1-dioxide) and certain 3-(alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxide derivatives inhibit insulin release by an activation of K_{ATP} -channels on pancreatic beta-cells (Pirotte B. et al. *Biochem. Pharmacol.* 47, 1381-1386 (1994); Pirotte B. et al., *J. Med. Chem.*, 36, 3211-3213 (1993). Diazoxide has furthermore been shown to delay the onset of diabetes in BB-rats (Vlahos WD et al. *Metabolism* 40, 39-46 (1991). In obese
30 zucker rats diazoxide has been shown to decrease insulin secretion and increase insulin receptor binding and consequently improve glucose tolerance and decrease weight gain (Alemzadeh R. et al. *Endocrinol.* 133, 705-712, 1993). It is expected that compounds

which activate K_{ATP} -channels can be used for treatment of diseases characterised by an overproduction of insulin and for the treatment and prevention of diabetes.


The following compounds are known from the literature:

- 5 3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-isobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- (2-ethylhexylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- cyclopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 10 cyclohexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-chloro-3-(1,2,2-trimethylpropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-chloro-3-(1,2-dimethylpropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-chloro-3-(1-methylpropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 15 7-chloro-3-cyclopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-chloro-3-cyclohexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-chloro-3-cyclopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6,7-dichloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 20 6,7-dichloro-3-cyclopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-isobutylamino-7-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-cyclopentylamino-7-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-cyclohexylamino-6-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
- (N-cyclohexyl-N-methylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 25 3-cyclohexylamino-4-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-cyclohexylamino-2-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide.

DESCRIPTION OF THE INVENTION

30

The present invention relates to 1,2,4-benzothiadiazine derivatives of the general formula I:



wherein


- 5 R¹ and R⁵ independently can be hydrogen; hydroxy; C₁₋₆-alkoxy; C₃₋₆-cycloalkyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen and R⁴ is hydrogen; or
- 10 R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3 of formula I and R¹ is as defined above; or
- R⁴ together with R¹ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I and R⁵ is as defined above;
- 15 D represents -S(=O)₂- or -S(=O)-;
- R² is hydrogen; hydroxy; C₁₋₆-alkoxy; C₃₋₆-cycloalkyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl
- 20 optionally mono- or polysubstituted with halogen;
- R³ is R⁸; -OR⁸; -C(=X¹)R⁸; ; bicycloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl optionally mono- or polysubstituted with halogen, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy, aryloxy, arylalkoxy, nitro, amino, C₁₋₆-monoalkyl- or dialkylamino, cyano, oxo, acyl or C₁₋₆-
- 25 alkoxycarbonyl;

wherein R⁸ is hydrogen; C₃₋₆-cycloalkyl or (C₃₋₆-cycloalkyl)C₁₋₆-alkyl the C₃₋₆-cycloalkyl

group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; a 3-6 membered saturated ring system comprising one or more nitrogen-, oxygen- or sulfur atoms, optionally being mono- or polysubstituted with halogen, cyano, trifluoromethyl, C₁₋₆-alkyl, C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, aryl, arylalkyl, hydroxy, oxo, nitro, amino, C₁₋₆-monoalkyl or dialkylamino; or straight or branched C₁₋₁₈-alkyl optionally mono- or polysubstituted with halogen, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkyl, aryl, aryloxy, arylalkoxy, nitro, amino, C₁₋₆-monoalkyl- or dialkylamino, cyano, oxo, formyl, acyl, carboxy, C₁₋₆-alkoxycarbonyl, carbamoyl, formylamino, or C₁₋₆-alkylcarbonylamino;

10 X¹ is O or S;

R³ is



15

wherein n,m,p independently can be 0,1,2,3 and R¹⁰ is hydrogen; hydroxy; C₁₋₆-alkoxy; C₃₋₆-cycloalkyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with
 20 halogen;

R¹², R¹³, R¹⁴, R¹⁵ independently are hydrogen; halogen; C₁₋₁₈-alkyl; C₃₋₆-cycloalkyl; hydroxy; C₁₋₆-alkoxy; C₁₋₆-alkoxy-C₁₋₆-alkyl; nitro; amino; cyano; cyanomethyl; perhalomethyl; C₁₋₆-monoalkyl- or dialkylamino; sulfamoyl; C₁₋₆-alkylthio; C₁₋₆-alkylsulfonyl; C₁₋₆-alkylsulfinyl; C₁₋₆-alkylcarbonylamino; formyl; arylthio, arylsulfinyl, arylsulfonyl, the aryl group optionally
 25 being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; C₁₋₆-alkoxycarbonyl; C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl; carbamyl; carbamylmethyl; C₁₋₆-monoalkyl- or dialkylaminocarbonyl; C₁₋₆-monoalkyl - or dialkylaminothiocarbonyl; ureido; C₁₋₆-

monoalkyl- or dialkylaminocarbonylamino, thioureido; C₁₋₆-monoalkyl- or dialkylaminothio-
carbonylamino; C₁₋₆-monoalkyl- or dialkylaminosulfonyl; carboxy; carboxy-C₁₋₆-alkyl; acyl;
aryl, arylalkyl, aryloxy, the aryl group optionally being mono- or polysubstituted with C₁₋₆-
alkyl, halogen, hydroxy or C₁₋₆-alkoxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl)-C₁₋₆-
5 alkyl the oxadiazolyl group optionally being substituted with C₁₋₆-alkyl or C₃₋₆-cycloalkyl; or
a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl;

Within its scope the invention includes all optical isomers of compounds of formula I, some
of which are optically active, and also their mixtures including racemic mixture thereof.

10

The scope of the invention also includes all tautomeric forms of the compounds of formula
I.

The salts include pharmaceutically acceptable acid addition salts, pharmaceutically
15 acceptable metal salts or optionally alkylated ammonium salts, such as hydrochloric,
hydrobromic, hydroiodic, phosphoric, sulfuric, trifluoroacetic, trichloroacetic, oxalic, maleic,
pyruvic, malonic, succinic, citric, tartaric, fumaric, mandelic, benzoic, cinnamic, methane-
sulfonic, ethane sulfonic, picric and the like, and include acids related to the pharmaceuti-
cally acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) and
20 incorporated herein by reference, or lithium, sodium, potassium, magnesium and the like.

The term "C₁₋₆-alkyl" as used herein, alone or in combination, refers to a straight or
branched, saturated hydrocarbon chain having 1 to 6 carbon atoms such as e.g. methyl,
ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-methylbutyl, 3-
25 methylbutyl, n-hexyl, 4-methylpentyl, neopentyl, n-hexyl, 1,2-dimethylpropyl, 2,2-
dimethylpropyl and 1,2,2-trimethylpropyl.

The term "C₁₋₆-alkoxy" as used herein, alone or in combination, refers to a straight or
branched monovalent substituent comprising a C₁₋₆-alkyl group linked through an ether
30 oxygen having its free valence bond from the ether oxygen and having 1 to 6 carbon
atoms e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy.

The term "C₁₋₆-alkylthio" as used herein, alone or in combination, refers to a straight or branched monovalent substituent comprising a lower alkyl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom and having 1 to 6 carbon atoms e.g. methylthio, ethylthio, propylthio, butylthio, pentylthio.

5

The term "C₂₋₆-alkenyl" as used herein refers to an unsaturated hydrocarbon chain having 2-6 carbon atoms and one double bond such as e.g. vinyl, 1-propenyl, allyl, isopropenyl, n-butenyl, n-pentenyl and n-hexenyl.

- 10 The term "C₃₋₆-cycloalkyl" as used herein refers to a radical of a saturated cyclic hydrocarbon with the indicated number of carbons such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

The term "C₂₋₆-alkynyl" as used herein refers to unsaturated hydrocarbons which contain

- 15 triple bonds, such as e.g. -C≡CH, -C≡CCH₃, -CH₂C≡CH, -CH₂CH₂C≡CH, -CH(CH₃)C≡CH, and the like.

The term "C₁₋₆-alkoxy-C₁₋₆-alkyl" as used herein refers to a group of 2-12 carbon atoms interrupted by an O such as e.g. CH₃-O-CH₃, CH₂-O-CH₂-CH₃, CH₂-O-CH(CH₃)₂ and the

20 like.

The term "halogen" means fluorine, chlorine, bromine or iodine.

The term "perhalomethyl" means trifluoromethyl, trichloromethyl, tribromomethyl or

25 triiodomethyl.

- The term "C₁₋₁₈-alkyl" as used herein refers to a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms such as e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 4-methylpentyl, neopentyl, n-hexyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1,2,2-trimethylpropyl and the like. The term "C₁₋₁₈-alkyl" as used herein also includes secondary C₃₋₆-alkyl and tertiary C₄₋₆-alkyl.
- 30

The term "C₁₋₆-monoalkylamino" as used herein refers to an amino group wherein one of the hydrogen atoms is substituted with a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms such as e.g. methylamino, ethylamino, 5 propylamino, n-butylamino, sec-butylamino, isobutylamino, tert-butylamino, n-pentylamino, 2-methylbutylamino, n-hexylamino, 4-methylpentylamino, neopentylamino, n-hexylamino, 2,2-dimethylpropylamino and the like.

The term "C₁₋₆-dialkylamino" as used herein refers to an amino group wherein the two 10 hydrogen atoms independently are substituted with a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms: such as dimethylamino, N-ethyl-N-methylamino, diethylamino, dipropylamino, N-(n-butyl)-N-methylamino, di(n-pentyl)amino, and the like.

15 The term "acyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-alkyl group linked through a carbonyl group; such as e.g. acetyl, propionyl, butyryl, isobutyryl, pivaloyl, valeryl, and the like.

The term "C₁₋₆-alkoxycarbonyl" as used herein refers to a monovalent substituent 20 comprising a C₁₋₆-alkoxy group linked through a carbonyl group; such as e.g. methoxycarbonyl, carbethoxy, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, 3-methylbutoxycarbonyl, n-hexoxycarbonyl and the like.

25 The term "3-6 membered saturated ring system" as used herein refers to a monovalent substituent comprising a monocyclic saturated system containing one or more hetero atoms selected from nitrogen, oxygen and sulfur and having 3-6 members and having its free valence from a carbon atom, e.g. 2-pyrrolidyl, 4-piperidyl, 3-morpholinyl, 1,4-dioxan-2-yl, 5-oxazolidinyl, 4-isoxazolidinyl, or 2-thiomorpholinyl.

30

The term "bicycloalkyl" as used herein refers to a monovalent substituent comprising a bicyclic structure made of 6-12 carbon atoms such as e.g. 2-norbornyl, 7-norbornyl, 2-

bicyclo[2.2.2]octyl, and 9-bicyclo[3.3.1]nonanyl.

The term "aryl" as used herein refers to phenyl, 1-naphthyl, or 2-naphthyl.

5 The term "heteroaryl" as used herein, alone or in combination, refers to a monovalent substituent comprising a 5-6 membered monocyclic aromatic system or a 9-10 membered bicyclic aromatic system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur, e.g. pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, isoxazole, oxazole, oxadiazole, thiadiazole, quinoline, isoquinoline, quinazoline, quinoxaline, indole, benzimidazole, benzofuran, pteridine, and
10 purine.

The term "arylalkyl" as used herein refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with an aromatic carbohydride; such as benzyl,
15 phenethyl, 3-phenylpropyl, 1-naphthylmethyl, 2-(1-naphthyl)ethyl and the like.

The term "aryloxy" as used herein refers to phenoxy, 1-naphthyloxy or 2-naphthyloxy.

The term "arylalkoxy" as used herein refers to a C₁₋₆-alkoxy group substituted with an
20 aromatic carbohydride, such as benzyloxy, phenethoxy, 3-phenylpropoxy, 1-naphthylmethoxy, 2-(1-naphthyl)ethoxy and the like.

The term "heteroarylalkyl" as used herein refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with a heteroaryl group; such as
25 (2-furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1-methyl-1-(2-pyrimidyl)ethyl and the like.

The term "C₁₋₆-alkylsulfonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-alkyl group linked through a sulfonyl group such as e.g. methylsulfonyl, ethylsul-
30 fonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, sec-butylsulfonyl, iso-butylsulfonyl, tert-butylsulfonyl, n-pentylsulfonyl, 2-methylbutylsulfonyl, 3-methylbutylsulfonyl, n-hexylsulfonyl, 4-methylpentylsulfonyl, neopentylsulfonyl, n-

hexylsulfonyl and 2,2-dimethylpropylsulfonyl.

The term "C₁₋₆-monoalkylaminosulfonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-monoalkylamino group linked through a sulfonyl group such as e.g.

5 methylaminosulfonyl, ethylaminosulfonyl, n-propylaminosulfonyl, isopropylaminosulfonyl, n-butylaminosulfonyl, sec-butylaminosulfonyl, isobutylaminosulfonyl, tert-butylaminosulfonyl, n-pentylaminosulfonyl, 2-methylbutylaminosulfonyl, 3-methylbutylaminosulfonyl, n-hexylaminosulfonyl, 4-methylpentylaminosulfonyl, neopentylaminosulfonyl, n-hexylaminosulfonyl and 2,2-dimethylpropylaminosulfonyl.

10

The term "C₁₋₆-dialkylaminosulfonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-dialkylamino group linked through a sulfonyl group such as dimethylaminosulfonyl, N-ethyl-N-methylaminosulfonyl, diethylaminosulfonyl, dipropylaminosulfonyl, N-(n-butyl)-N-methylaminosulfonyl, di(n-pentyl)aminosulfonyl, and the like.

15

The term "C₁₋₆-alkylsulfinyl" as used herein refers to a monovalent substituent comprising a straight or branched C₁₋₆-alkyl group linked through a sulfinyl group (-S(=O)-); such as e.g. methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, butylsulfinyl, pentylsulfinyl, and the like.

20 The term "C₁₋₆-alkylcarbonylamino" as used herein refers to an amino group wherein one of the hydrogen atoms is substituted with an acyl group, such as e.g. acetamido, propionamido, isopropylcarbonylamino, and the like.

The term "(C₃₋₆-cycloalkyl)C₁₋₆-alkyl" as used herein, alone or in combination, refers to a
25 straight or branched, saturated hydrocarbon chain having 1 to 6 carbon atoms and being monosubstituted with a C₃₋₆-cycloalkyl group, the cycloalkyl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; such as e.g. cyclopropylmethyl, (1-methylcyclopropyl)methyl, 1-(cyclopropyl)ethyl, cyclopentylmethyl, cyclohexylmethyl, and the like.

30

The term "arythio" as used herein, alone or in combination, refers to an aryl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom, the aryl

group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; e.g. phenylthio, (4-methylphenyl)-thio, (2-chlorophenyl)thio, and the like.

The term "arylsulfinyl" as used herein refers to an aryl group linked through a sulfinyl group (-S(=O)-), the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; such as e.g. phenylsulfinyl, (4-chlorophenyl)sulfinyl, and the like.

The term "arylsulfonyl" as used herein refers to an aryl group linked through a sulfonyl group, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; such as e.g. phenylsulfonyl, tosyl, and the like.

The term "C₁₋₆-monoalkylaminocarbonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-monoalkylamino group linked through a carbonyl group such as e.g. methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl, n-butylaminocarbonyl, sec-butylaminocarbonyl, isobutylaminocarbonyl, tert-butylaminocarbonyl, n-pentylaminocarbonyl, 2-methylbutylaminocarbonyl, 3-methylbutylamino-carbonyl, n-hexylaminocarbonyl, 4-methylpentylaminocarbonyl, neo-pentylaminocarbonyl, n-hexylaminocarbonyl and 2-2-dimethylpropylaminocarbonyl.

The term "C₁₋₆-dialkylaminocarbonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-dialkylamino group linked through a carbonyl group such as dimethylaminocarbonyl, N-ethyl-N-methylaminocarbonyl, diethylaminocarbonyl, dipropylaminocarbonyl, N-(n-butyl)-N-methylaminocarbonyl, di(n-pentyl)aminocarbonyl, and the like.

The term "C₁₋₆-monoalkylaminocarbonylamino" as used herein refers to an amino group wherein one of the hydrogen atoms is substituted with a C₁₋₆-monoalkylaminocarbonyl group, e.g. methylaminocarbonylamino, ethylaminocarbonylamino, n-propylaminocarbonylamino, isopropylaminocarbonylamino, n-butylaminocarbonylamino, sec-butylaminocarbonylamino, isobutylaminocarbonylamino, tert-butylaminocarbonylamino, and 2-methylbutylaminocarbonylamino.

The term "C₁₋₆-dialkylaminocarbonylamino" as used herein refers to an amino group wherein

one of the hydrogen atoms is substituted with a C₁₋₆-dialkylaminocarbonyl group, such as dimethylaminocarbonylamino, N-ethyl-N-methylaminocarbonylamino, diethylaminocarbonylamino, dipropylaminocarbonylamino, N-(n-butyl)-N-methylaminocarbonylamino, di(n-pentyl)aminocarbonylamino, and the like.

5

The term "5- or 6-membered nitrogen containing ring" as used herein refers to a monovalent substituent comprising a monocyclic unsaturated or saturated system containing one or more nitrogen atoms and having 5 or 6 members, e.g. pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, pyrrolyl, 2H-pyrrolyl, imidazolyl, 10 pyrazolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, morpholino, thiomorpholino, isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, 1,3-dioxolanyl, and 1,4-dioxolanyl.

In a preferred embodiment of the invention one of R¹ and R⁵ is hydrogen; hydroxy; C₁₋₆-alkoxy; C₃₋₆-cycloalkyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or 15 C₁₋₆-alkoxy; C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen; and the other of R¹ and R⁵ together with R⁴ is a bond. Preferably one of R¹ and R⁵ is hydrogen; and the other of R¹ and R⁵ together with R⁴ is a bond.

20 In another preferred embodiment of the invention R² is hydrogen or C₁₋₆-alkyl. Preferably R² is hydrogen.

In another preferred embodiment of the invention R³ is R⁸, -OR⁸, -C(=O)R⁸; wherein R⁸ is hydrogen; C₃₋₆-cycloalkyl or (C₃₋₆-cycloalkyl)C₁₋₆-alkyl, C₃₋₆-cycloalkyl optionally being mono- 25 or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; a 3-6 membered saturated ring system comprising one or more nitrogen-, oxygen- or sulfur atoms; or straight or branched C₁₋₁₈-alkyl optionally mono- or polysubstituted with halogen, C₃₋₆-cycloalkyl, hydroxy or C₁₋₆-alkoxy;

30 In yet another preferred embodiment of the invention R³ is selected from secondary C₃₋₆-alkyl, tertiary C₄₋₆-alkyl, C₃₋₆-cycloalkyl or (C₃₋₆-cycloalkyl)methyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy. Preferably R³ is selected from

isopropyl, 1-methylpropyl, 2-methylpropyl, tert-butyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1,2,2-trimethylpropyl, 2,3-dimethylbutyl, 1-ethylpropyl, 1-ethyl-2-methylpropyl, 1-ethyl-2,2-dimethylpropyl, 2,3,3-trimethylbutyl, 2-methylbutyl, cyclopropyl, 1-methylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, 1-(cyclopropyl)ethyl, cyclobutylmethyl, 5 cyclopentylmethyl or cyclohexylmethyl.

In another preferred embodiment of the invention R^{12} , R^{13} , R^{14} , R^{15} are selected from hydrogen; halogen; C_{1-18} -alkyl; C_{3-6} -cycloalkyl; cyano; cyanomethyl; perhalomethyl; sulfamoyl; C_{1-6} -alkylthio; C_{1-6} -alkylsulfonyl; C_{1-6} -alkylsulfinyl; arylthio, arylsulfinyl, arylsulfonyl, the 10 aryl group optionally being mono- or polysubstituted with C_{1-6} -alkyl, halogen, hydroxy or C_{1-6} -alkoxy; C_{1-6} -alkoxycarbonyl- C_{1-6} -alkyl; carbamylmethyl; carboxy- C_{1-6} -alkyl; aryloxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl) C_{1-6} -alkyl, the oxadiazolyl group optionally being substituted with C_{1-6} -alkyl or C_{3-6} -cycloalkyl; acyl; or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C_{1-6} -alkyl.

15 Preferred compounds of the invention are:

- 3-Benzoyloxyamino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Chloro-3-methoxyamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Bromo-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 20 7-Chloro-3-(N-ethyl-N-methylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Chloro-3-methoxyamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Chloro-3-(1,2,2-trimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Bromo-3-(1,2,2-trimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Chloro-3-(N-ethyl-N-methylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 25 5-Amino-7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Chloro-3-(1,3-dimethylpentyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Chloro-3-(1,5-dimethylhexyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Chloro-3-(1,4-dimethylpentyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 5,7-Dichloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 30 7-Bromo-6-trifluoromethyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Chloro-3-(3,3-diphenylpropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Chloro-3-(4-phenylbutylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 7-Chloro-3-(3-diethylamino-1-methylpropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-4H-1,2,4-benzothiadiazine-5-carboxaldehyde 1,1-dioxide
3-Isopropylamino-4H-1,2,4-benzothiadiazine-7-carboxaldehyde 1,1-dioxide
3-Isopropylamino-4H-1,2,4-benzothiadiazine-6-carboxylic acid 1,1-dioxide
5 7-Cyano-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-7-iodo-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-cyanomethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
5,7-Dichloro-3-isopropylamino-6-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(3-(1H-imidazol-4-yl)propyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
10 3-Isopropylamino-6,7-dimethoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-(1-Azabicyclo[2.2.2]oct-3-yl)amino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-(1,2-dimethylpropyl)amino-7-sulfamoyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Anilino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
15 7-Chloro-3-(imidazol-2-yl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(4-pyridyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-isobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-sec-Butylamino-6-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-cyclohexylmethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
20 6-Fluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclopentylamino-6-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-isopropylamino-5-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-tert-Butylamino-6-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Iodo-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
25 6-Chloro-7-fluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-6-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-cyclopropylmethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-7-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
5,7-Dibromo-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
30 6-Acetyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Allylamino-6-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-(1-ethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 6-Chloro-3-butylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-hexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Dichloro-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Dichloro-3-(1-methylbutyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
5 7-Chloro-3-(1,2-dimethylpropyl)amino-2-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
6,8-Dichloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-isopropylamino-2-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-6-benzenesulfonyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-6-methanesulfonyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
10 5-Chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-6-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-isopropylamino-7-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Ethoxycarbonylmethyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Carboxymethyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
15 8-Chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Isopropyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-tert-Butyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-6-phenoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Hexyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
20 6-Cyclohexyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
2-(3-Isopropylamino-1,1-dioxo-1,4-dihydro-1 λ ⁶,2,4-benzothiadiazin-6-yl)-acetamide
6-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)methyl-3-isopropylamino-4H-1,2,4-benzothiadiazine
1,1-dioxide
6-Cyanomethyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
25 7-Chloro-3-(2-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-sec-Butylamino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Iodo-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Iodo-3-(1,2,2-trimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-cyclohexylmethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
30 (R)-7-Chloro-3-(1-cyclohexylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
(S)-7-Chloro-3-(1-cyclohexylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
(R)-7-Chloro-3-(1-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

- (S)-7-Chloro-3-(1-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclohexylmethylamino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide
(R)-3-(1-Cyclohexylethyl)amino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide
(S)-3-(1-Cyclohexylethyl)amino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide
5 3-Benzylamino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide
(R)-7-Iodo-3-(1-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
(S)-7-Iodo-3-(1-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-sec-Butylamino-7-bromo-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Bromo-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
10 7-Fluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-sec-Butylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Bromo-3-cyclopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
15 7-Chloro-3-(2,2,2-trifluoroethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Allylamino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(2-methoxy-1-methylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(1-ethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
20 3-(1-Ethylpropyl)amino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-sec-Butylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-(1,2-Dimethylpropyl)amino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(2-hydroxypropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(2-hydroxy-1-methylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
25 3-(2-Aminoethyl)amino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(2,2-diethoxyethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Ethylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclopropylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
30 3-Cyclobutylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclopentylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclopropylmethylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 3-Allylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-(2-methoxy-1-methylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-(2,2,2-trifluoroethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
5 7-Bromo-3-methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Bromo-3-ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Bromo-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Bromo-3-(2,2,2-trifluoroethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
10 7-Chloro-3-hexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Dichloro-3-hexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-(2,2-Diethoxyethyl)amino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-(2,2,2-trifluoroethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Bromo-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
15 6-Chloro-3-cyclopropylmethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclopropylmethylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Nitro-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclobutylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Dichloro-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
20 7-Amino-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Acetamido-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclobutylamino-7-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Methoxy-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
25 7-Chloro-3-(2-formylaminoethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-(2-Acetylaminoethyl)amino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
5-Chloro-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
5-Chloro-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
5-Chloro-3-hexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
30 6-Chloro-3-octylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-(1,5-dimethylhexyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 3-sec-Butylamino-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-4H-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide
3-sec-Butylamino-4H-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide
3-Propylamino-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
5 3-Cyclopropylmethylamino-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Propylamino-4H-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide
7-Chloro-3-(pyridin-2-yl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Ethylamino-6,7-difluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3,6-di(isopropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
10 6,8-Difluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Difluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7,8-Trifluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-isopropylamino-6-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-isopropylamino-6-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide
15 6,8-Dichloro-3-ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,8-Dichloro-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,8-Dichloro-3-cyclopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,8-Dichloro-3-cyclopropylmethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,8-Dichloro-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
20 6,8-Dichloro-3-cyclopentylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(2-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(3-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(4-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(2-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
25 7-Chloro-3-(3-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(4-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-(2-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-(3-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-(4-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
30 6-Chloro-3-(2-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-(3-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-(4-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 7-Fluoro-3-(2-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-(3-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-(4-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-(2-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
5 7-Fluoro-3-(3-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-(4-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Fluoro-3-(2-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Fluoro-3-(3-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Fluoro-3-(4-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
10 6-Fluoro-3-(2-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Fluoro-3-(3-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Fluoro-3-(4-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Dichloro-3-(2-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Dichloro-3-(3-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
15 6,7-Dichloro-3-(4-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Dichloro-3-(2-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Dichloro-3-(3-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Dichloro-3-(4-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,8-Dichloro-3-(2-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
20 6,8-Dichloro-3-(3-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,8-Dichloro-3-(4-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,8-Dichloro-3-(2-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,8-Dichloro-3-(3-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,8-Dichloro-3-(4-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
25 6,7-Difluoro-3-(2-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Difluoro-3-(3-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Difluoro-3-(4-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Difluoro-3-(2-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Difluoro-3-(3-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
30 6,7-Difluoro-3-(4-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,8-Difluoro-3-(2-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,8-Difluoro-3-(3-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 6,8-Difluoro-3-(4-pyridyl)methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6,8-Difluoro-3-(2-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6,8-Difluoro-3-(3-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6,8-Difluoro-3-(4-pyridyl)ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 5 6,8-Bis(trifluoromethyl)-3-(1,4-dimethylpentyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6,8-Bis(trifluoromethyl)-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6,8-Bis(trifluoromethyl)-3-cyclopentylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6,8-Bis(trifluoromethyl)-3-cyclopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6,8-Bis(trifluoromethyl)-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 10 6,8-Bis(trifluoromethyl)-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6,8-Bis(trifluoromethyl)-3-ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

The compounds of the present invention interact with the potassium channels and hence act as openers or blockers of the ATP-regulated potassium channels, which make them

15 useful in the treatment of various diseases of the cardiovascular system, e.g. cerebral ischemia, hypertension, ischemic heart diseases, angina pectoris and coronary heart diseases; the pulmonary system; the gastrointestinal system; the central nervous system and the endocrinological system.

20 Since some K_{ATP} -openers are able to antagonize vasospasms in basilar or cerebral arteries the compounds of the present invention can be used for the treatment of vasospastic disorders such as vasospastic disorders, subarachnoid haemorrhage and migraine.

25 The compounds of the present invention may also be used for the treatment of diseases associated with decreased skeletal muscle blood flow such as Raynauds disease and intermittent claudication.

Further, the compounds of the invention may be used for the treatment of chronic airway

30 diseases, including asthma, and for treatment of detrusor muscle instability secondary to bladder outflow obstruction and therefore for kidney stones by aiding their passage along the urethra.

The present compounds could also be used for treatment of conditions associated with disturbances in gastrointestinal mobility such as irritable bowel syndrome. Additionally these compounds can be used for the treatment of premature labour and dysmenorrhea.

5

Potassium channel openers hyperpolarizes neurons and inhibit neurotransmitter release and it is expected that such compounds can be used for the treatment of various diseases of the central nervous system, e.g. epilepsy, ischemia and neurodegenerative diseases, and for the management of pain.

10

Further, potassium channel openers promote hairgrowth, therefore, the compounds of the present invention can be used for the treatment of baldness.

Potassium channel openers also relax urinary bladder smooth muscle, thus, the

15 compounds of the present invention can be used for the treatment of urinary incontinence.

In diseases such as nesidioblastosis and insulinoma in which a hypersecretion of insulin causes severe hypoglycemia the compounds of the present invention can be used to reduce insulin secretion. In obesity hyperinsulinemia and insulin resistance is very

20 frequently encountered. This condition could lead to the development of noninsulin dependent diabetes (NIDDM). It is expected that potassium channel openers and hence the compounds of the present invention can be used for reducing the hyperinsulinemia and thereby prevent diabetes and reduce obesity. In overt NIDDM treatment of hyperinsulinemia with potassium channel openers, and hence the present compounds, 25 can be of benefit in restoring glucose sensitivity and normal insulin secretions.

In early cases of insulin dependent diabetes (IDDM) or in prediabetic cases, potassium channel openers and hence the present compounds can be used to induce betacell rest which may prevent the progression of the autoimmune disease.

30

The potassium channel openers of the present invention can be administered in combination with an immunosuppressant or with an agent like nicotinamide, which will

reduce autoimmune degeneration of beta-cells.

Combining beta-cell rest with a treatment protecting the beta-cells against cytokine mediated beta-cell impairment/cytotoxicity is another aspect of this invention.

5 Insulin requiring or Type 1 diabetes (IDDM) as well as late onset IDDM (also known as type 1.5. e.g. non-insulin-requiring Type 2 (NIDDM) patients with autoreactivity against beta-cell epitopes that later turns insulin requiring) have circulating autoreactive monocytes/lymphocytes that homes to the islets/beta-cells and releases their cytokines. Some of these cytokines (e.g. interleukin-1b (IL-1b) , tumour necrosis factor a (TNFa) and
10 interferon g (IFNg)) are specifically toxic to the beta-cells, e.g. through the induction of nitric oxide (NO) and other free radicals. Inhibition of this cytotoxicity, e.g. by co-administring nicotinamide (NA), a derivative hereof or other cytokine protective compounds to the prediabetic/diabetic patients treated with the PCO compound is an example of this aspect. Nicotinamide belongs to the B-vitamin family and is derived from nicotinic
15 acid by amidation of the carboxyl group. It processes none of nicotine's pharmacological properties. NA is converted into NAD⁺, which acts as a coenzyme for proteins involved in tissue respiration. NA has been proposed to influence several of the putative intracellular molecular events following immune attack on the beta-cells. Animal experiments and early non-blinded experiments in humans have indicated a protective role of this compound
20 against IDDM as well as in cytokine/immune mediated beta-cell destruction.

Yet another aspect of this application concerns the use of a PCO compound alone or in combination with the inhibitor of cytokine/immune mediated beta-cell impairment , in transplantation, e.g. islet transplantation into diabetes patients. The use of one or both of these treatments may reduce the risk of rejection of the transplanted islets/beta-
25 cells/engineered beta-cells/pancreas.

Compounds of the present invention which act as blockers of K_{ATP} -channels can be used for the treatment of NIDDM.

30

Preferably, the compounds of the present invention may be used for treatment or prevention of diseases of the endocrinological system such as hyperinsulinaemia and


diabetes.

Accordingly, in another aspect the invention relates to a compound of the general formula I or a pharmaceutically acceptable acid addition salt thereof for use as a therapeutically acceptable substance, preferably for use as a therapeutically acceptable substance in the treatment of hyperinsulinaemia and treatment or prevention of diabetes.

Furthermore, the invention also relates to the use of the inventive compounds of formula I as medicaments useful for treating hyperinsulinaemia and treating or preventing diabetes.

In yet another aspect, the present invention relates to methods of preparing the above mentioned compounds. The methods comprises:


a) reacting a compound of formula II:



(II)

wherein D, R¹, R⁴, R⁵, R¹², R¹³, R¹⁴ and R¹⁵ are as defined above and Z is a leaving group such as alkoxy, alkylthio, halogen, preferentially chloro, bromo, iodo, amino, trimethylamino, imidazol-1-yl, methylsulfinyl or methylsulfonyl with a compound of formula III:

24




(III)

wherein R^2 and R^3 are defined above to form a compound of the general formula I using
 5 e.g. procedures described by T. H. Cronon et al., *J. Med. Chem.* **11**, 136 (1968); L. Raffa
 et al., *Farmaco Ed. Sci.* **29**, 411 (1974); B. Pirotte et al., *J. Med. Chem.* **36**, 3211 (1993),
 H.J. Petersen, *Acta Chem. Scand.* **27**, 2655(1973).

Another method comprises:

10

b) reacting a compound of formula IV:



15


(IV)

20 wherein R^1 is hydrogen and D, R^5 , R^{12} , R^{13} , R^{14} , and R^{15} are as defined above, or R^5 is H
 and R^1 , R^{12} , R^{13} , R^{14} , R^{15} and D are as defined above, with the compound of formula III, or
 a suitable salt thereof in the presence of P_2O_5 and a high boiling tertiary amine or a
 suitable salt thereof using a procedure described by Jensen K.G. and Pedersen E.B.,
Chem. Scr., **20**, 248-250 (1988) and Andersen L., Nielsen F.E. and Pedersen E.B., *Chem.*
 25 *Scr.*, **29**, 45-49 (1989), to form a compound of the general formula I.

25

c) reacting a compound of the formula IV:

5




(IV)

10 wherein R¹ is hydrogen and D, R⁵, R¹², R¹³, R¹⁴ and R¹⁵ are as defined above or R⁵ is H and R¹, R¹², R¹³, R¹⁴, R¹⁵ and D are as defined above, with a compound of the formula III, or a suitable salt thereof in the presence of titanium tetrachloride and a solvent with which it may form a complex, like e.g. tetrahydrofuran, or a mixture of toluene and anisole, according to the methods described in R.I. Fryer, J.V. Earley, G.F. Field, W. Zally, and
 15 L.H. Sternbach, *J.Org.Chem.* 34, 1143-1145 (1969); J.B. Press et al., *J.Med.Chem.* 22, 725-731 (1979); or G. Roma et al. *Eur.J.Med.Chem.* 26, 489-496 (1991), to form a compound of the general formula I.

d) reacting a compound of formula V

20



(V)


wherein R^1 , R^{12} , R^{13} , R^{14} and R^{15} are as defined above, with a compound of formula VI



wherein R^3 is as defined above using the method described by Chern J.W. et al., *J. Heterocycl. Chem.*, 27, 1909-1915 (1990), to form a compound of the general formula I, wherein D is SO_2 , R^2 is H, and R^4 and R^5 together form a bond.

10

e) reacting a compound of the formula V



15

(V)

wherein R^1 , R^{12} , R^{13} , R^{14} and R^{15} are as defined above, with a compound of formula VII

20




wherein R^3 is as defined above using the method described by Chern J.W. et al., *J. Heterocycl. Chem.*, 27, 1909-1915 (1990), to form a compound of the general formula I,


25 wherein D is SO_2 , R^2 is H, and R^4 and R^5 together form a bond.

f) reacting a compound of the formula V

27



wherein R^1 , R^{12} , R^{13} , R^{14} and R^{15} are defined as above, with a compound of formula VIII




(VIII)

wherein Y is NH or S , or a suitable salt thereof using procedures described by Kotovskaya S.K. et al., *Khim.-Farm. Zh.*, 13, 54-57 (russ.) (1979) and Topliss J.G. et al., *J. Org. Chem.*, 28, 2313 (1963), to form a compound of the general formula I, wherein D is SO_2 , R^4 and R^5 together form a bond, and R^2 and R^3 are H .

g) reacting a compound of the formula V


28



(V)

wherein R¹, R¹², R¹³, R¹⁴ and R¹⁵ are as defined above, with a compound of formula IX


5



(IX)

wherein R³ is as defined above, using e.g. the procedures described by Topliss et al., J. Org. Chem., 28, 2313 (1963), to form a compound of the general formula I, wherein D is
10 SO₂, R² is H, and R⁴ and R⁵ together form a bond;

h) reacting in the presence of a base a compound of formula X




15

(X)

or a suitable salt thereof, wherein R¹¹ is R¹ or EtOC(=O), wherein R¹, R¹², R¹³, R¹⁴ and R¹⁵ are as defined above, with a compound of formula IX


20



(IX)


wherein R³ is as defined above, to form an adduct which may have either of the two structures XI or XII or be a mixture of the two

29



(XI)

5




(XII)

10


either of which by ring-closure, e.g. by treatment with phosgene in a suitable solvent, forms a compound of the general formula I, if R^{11} is R^1 , wherein D is SO_2 , R^2 is H, and R^4 and R^5 together form a bond, and a compound of the general formula XIII if R^{11} is $EtOC(=O)$;

15



(XIII)


i) hydrolyzing and subsequently decarboxylating a compound of the general formula XIII



(XIII)

e.g. by heating the compound in aqueous base and subsequently neutralizing with an acid, to form a compound of the general formula I, wherein D is SO_2 , R^1 and R^2 are H, and R^4 and R^5 together form a bond, and R^3 , R^{12} , R^{13} , R^{14} and R^{15} are as defined above.


j) reacting a compound of formula



(XIV)

wherein R^{12} , R^{13} , R^{14} and R^{15} are as defined above with thiocarbonyldiimidazole in a suitable solvent, like e.g. dioxane, to form a compound of formula


31



(XV)

which by treatment with an amine of formula III

5



(III)

forms a compound of the general formula I, wherein D is SO₂, R¹ is H, R⁴ and R⁵ together form a bond, and R², R³, R¹², R¹³, R¹⁴ and R¹⁵ are as defined above. The reaction may take place with or without a solvent and preferentially at elevated temperatures, e.g. in the range 100 - 150 °C. For volatile amines, the reaction may be carried out in a sealed vessel.

Compounds of the general formula I may also undergo chemical transformations in one or more steps by conventional methods to form other compounds of the general formula I wherein D, R¹, R², R³, R⁴, R⁵, R¹², R¹³, R¹⁴ and R¹⁵ are as defined above, e.g. by transformation of functional groups of (I) or by direct introduction of new substituents, e.g. on an aromatic ring. Such chemical transformations may consist of e.g. electrophilic substitution, nucleophilic substitution, nitration, alkylation, acylation, metalation followed by reaction with electrophiles, halogenation, reduction, oxidation, diazotization, and dehydration.

The starting materials are either known compounds or compounds which may be prepared in analogy with the preparation of known compounds or in analogy with known methods as described by e.g. Y. Girard et al., *J. Chem. Soc. Perkin I*, 1043, 1979, D.F. Hayman et al., *J. Pharm. Pharmacol.*, 522, 1962 (3-oxo-2,3-dihydro-4H-1,2,4-benzothiadiazine 1,1-dioxides), DiBella et al., *Il Farmaco Ed. Sci.* 21, 829, 1966 (3-thioxo-

2,3-dihydro-4H-1,2,4-benzothiadiazine 1,1-dioxides), DiBella et al., *Il Farmaco Ed. Sci.* 27, 990, 1972 (3-methylsulfanyl-4H-1,2,4-benzothiadiazine 1,1-dioxides), Szabo, *Bull. Soc. Chim. Fr.*, 1953, 771, Bierbaum, B.A. et al., *J. Med. Chem.* 6, 1963, 272-275 (4-amino-3-sulfamoylbenzoic acid), Patent, Farbwerke Hoechst, FR 1381634, 1962 (2-chloro-5-trifluoromethyl-benzenesulfonamide and 2-benzylamino-5-trifluoromethyl-benzenesulfonamide), Short, J.H.; Biermacher, U., *J. Amer. Chem. Soc.*, 82, 1960, 1135-1138 (2-amino-4,5-dichlorobenzenesulfonamide), Patent, Aktieselskabet Ferrosan, Ger. 1,135,483, 1962, (2-amino-4,6-dichlorobenzenesulfonamide), H.J. Petersen, *Acta Chem. Scand.* 27, 2655(1973).

10

PHARMACOLOGICAL METHODS

The ability of the compounds to interact with potassium channels can be determined by various methods. When patch-clamp techniques (Hamill O.P., Marty A., Neher E., Sakmann B. and Sigworth F.J., *Plügers Arch.*, 391, 85-100 (1981)) are used the ionic current through a single channel of a cell can be recorded.

The activity of the compounds as potassium channel openers can also be measured as relaxation of rat aortas rings according to the following procedure:

20

A section of rat thoracic aorta between the aortic arch and the diaphragm was dissected out and mounted as ring preparations as described by Taylor P.D. et al, *Brit J. Pharmacol*, 111, 42-48 (1994).

25 After a 45 min. equilibration period under a tension of 2 g, the preparations were contracted to achieve 80% of the maximum response using the required concentration of phenylephrine. When the phenylephrine response reached a plateau, potential vasodilatory agents were added cumulatively to the bath in small volumes using half log molar increments at 2 min intervals. Relaxation was expressed at the percentage of the contracted tension. The potency of a compound was expressed as the concentration required to evoke a 50% relaxation of the tissue.

30

Relaxation of rat aorta rings

<u>Example</u>	<u>EC50 micro M</u>
50	5.2
5 101	14.1
88	32.7
94	4.8

In the pancreatic b-cell the opening of the K_{ATP} -channels can be determined by measuring the subsequent change in the concentration of cytoplasmic free Ca^{2+} concentration according to the method of Arkhammar P. et al. , *J. Biol. Chem.*, 262, 5448-5454 (1987).

 $^{86}Rb^{+}$ efflux from a β -cell line

15 The RIN 5F cell line was grown in RPMI 1640 with Glutamax I, supplemented with 10 % fetal calf serum (from GibcoBRL, Scotland, UK) and maintained in an atmosphere of 5 % CO_2 / 95 % air at 37°C. The cells were detached with a Trypsin-EDTA solution (from GibcoBRL, Scotland, UK), resuspended in medium, added 1 mCi/ml $^{86}Rb^{+}$ and replated into microtiter plates (96 well cluster 3596, sterile, from Costar Corporation, MA, USA) at a density of 50000 cells/well in 100 μ l/well, and grown 24 hours before use in assay.

The plates were washed 4 times with Ringer buffer (150 mM NaCl, 10 mM Hepes, 3.0 mM KCl, 1.0 mM $CaCl_2$, 20 mM Sucrose, pH 7.1). Eighty μ l Ringer buffer and 1 μ l control- or test compound dissolved in DMSO was added. After incubation 1 h at room temperature with a lid, 50 μ l of the supernatant was transferred to PicoPlates (Packard Instrument Company, CT, USA) and 100 μ l MicroScint40 (Packard Instrument Company, CT, USA) added. The plates were counted in TopCount (Packard Instrument Company, CT, USA) for 1 min/well at the ^{32}P program.

30 The calculation of EC_{50} and E_{max} was done by SlideWrite (Advanced Graphics Software, Inc., CA, USA) using a four parameter logistic curve: $y = (a-d)/(1+(x/c)^b)+d$, where a = the activity estimated at concentration zero, b = a slope factor, c = the concentration at the middle of the curve and, d = the activity estimated at infinite concentration. $EC_{50} = c$ and

E_{\max} = d, when the curve is turned of at infinite concentrations.

Increased Rb-efflux in rin 5F cells

Example	EC50 micro M
---------	--------------

5

26	12.9
66	9.4
86	13.0

- 10 The compounds according to the invention are effective over a wide dosage range. In general satisfactory results are obtained with dosages from about 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, per day. A most preferable dosage is about 1 mg to about 100 mg per day. The exact dosage will depend upon the mode of administration, form in which administered, the subject to be treated and the body weight of the
- 15 subject to be treated, and the preference and experience of the physician or veterinarian in charge.

The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g.

20 rectal, transdermal, subcutaneous, intravenous, intramuscular or intranasal, the oral route being preferred.

Typical compositions include a compound of formula I or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient which

25 may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in form of a capsule, sachet, paper or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule,

30 sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for

example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.

10

The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.

- 15 For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.

Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.

Generally, the compounds are dispensed in unit form comprising from about 1 to about 25 100 mg in a pharmaceutically acceptable carrier per unit dosage.

A typical tablet, appropriate for use in this method, may be prepared by conventional tableting techniques and contains:

30 Active compound	5.0 mg
Lactosum	67.8 mg Ph.Eur.
Avicel®	31.4 mg

Amberlite® 1.0 mg
Magnesii stearas 0.25 mg Ph.Eur.

EXAMPLES

5

The process of preparing the compounds of formula I is further illustrated in the following examples which, however, are not to be construed as limiting.

10 General procedures for the preparation of the 3-alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides

Method A

15

A mixture of the appropriate 3-methylsulfanyl-substituted or 3-(imidazol-1-yl)-substituted benzothiadiazine 1,1-dioxide (0.5 g) and the appropriate alkylamine (5 mL) was heated in a sealed vessel at 120-150°C for 4-8 h (until completion of the reaction monitored by t.l.c.). The excess of amine was removed by distillation under reduced pressure and the
20 oily residue was dispersed in water. The suspension was supplemented with 2.5N NaOH until complete dissolution. The resulting solution was treated with charcoal, filtered, and the filtrate was adjusted to pH 5-6 with 6N HCl. The precipitate was collected by filtration, washed with water and recrystallized from methanol-water (yields: 60-90%).

25 Method B

A mixture of the appropriate 3-methylsulfanyl-substituted or 3-(imidazol-1-yl)-substituted benzothiadiazine 1,1-dioxide (0.5 g) and the appropriate alkylamine (5 mL) was refluxed for 2-120 h (until completion of the reaction monitored by t.l.c.). The final compound was
30 then isolated and purified as reported in method A (yields: 60-90%).

Method C

A mixture of the appropriate 3-methylsulfanyl-substituted or 3-(imidazol-1-yl)-substituted benzothiadiazine 1,1-dioxide (0.5 g) and the appropriate alkylamine (1 mL) in 3-chlorotoluene (5 mL) was refluxed for 1-3 h (until completion of the reaction monitored by t.l.c.). Most of the solvent and the excess of amine was removed by distillation, and the
5 oily residue was dispersed in a 1:1 mixture of methanol and water (50-100 mL). A 10% aqueous solution of NaOH was added dropwise until dissolution of most of the insoluble material. The alkaline medium was treated with charcoal, filtered, and the filtrate was adjusted to pH 5-6. The precipitate was collected by filtration, washed with water and recrystallized from methanol-water (yields: 60-90%).

10

Method D

A mixture of the appropriate 3-methylsulfanyl-substituted or 3-(imidazol-1-yl)-substituted benzothiadiazine 1,1-dioxide (0.6 g) and the appropriate alkylamine (1 mL) in dioxane (5
15 mL) was heated in a sealed vessel at 120-150°C for 4-8 h (until completion of the reaction monitored by t.l.c.). The final compound was then isolated and purified as reported in method A (yields: 60-90%).

EXAMPLE 1

20 7-Chloro-3-(2-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

2-Phenylethyl isothiocyanate (0.36 g) was added to a stirred slurry of 2-amino-5-chlorobenzenesulfonamide sodium salt (0.50 g) in 5 ml of acetonitrile at 60 °C. After 2½ h an additional amount of 2-phenylethyl isothiocyanate (0.18 g) was added, and the
25 temperature was raised to 90 °C for 1½ h. The reaction mixture was treated with 1 ml of 4M acetic acid, 5 ml of ethanol and 0.1 g of charcoal and filtered through celite. The solvent was evaporated and the residue extracted with 10 ml of ethyl acetate. The solvent was evaporated and the oily residue was purified on a silica column eluted with ethyl acetate. The title compound was obtained as white crystals; m.p. 250-252 °C.

30

EXAMPLE 2

7-Bromo-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

To a suspension of 2-amino-5-bromobenzenesulfonamide (0.8 g; 3.2 mmol) and potassium carbonate (0.54 g; 3.9 mmol) in acetone (20 ml) was added isopropyl isothiocyanate (0.387 g; 3.84 mmol). The mixture was heated to 60 °C and after 16 hr cooled, concentrated *in vacuo* and the crude residue was taken up in tetrahydrofuran (50 ml) and cooled to 0 °C. To the cooled mixture was added triethylamine (0.648 g; 6.4 mmol) followed by the addition of phosgene in toluene 1.9 M (1.82 ml) over 2 min. After 1 hr at 0 °C the mixture was concentrated *in vacuo*. The crude product was taken up in water (10 ml) and pH was adjusted to 6 with sodium bicarbonate. The precipitated product was collected by filtration and dried *in vacuo* at 50 °C for 16 hr giving 390 mg (38.3 %) of the title compound; m.p. >220 °C.

¹H-NMR (DMSO-d₆) ppm; 10.49 (br s, 1H, NH), 7.75 (m, 2H, H-6 and H-8), 7.21 (s, 1H, H-5), 7.15 (s, 1H, NH), 3.97 (m, 1H, CH) 1.19 (d, 6H, 2xCH₃).

15

EXAMPLE 36,8-Dichloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

A mixture of 2-amino-4,6-dichlorobenzenesulfonamide (1.0 g), isopropyl isothiocyanate (0.84 g), copper(I) chloride (0.4 g), and DMF (1.5 ml) was heated at 100 °C for 2 h. Then 5 ml of methanol was added and the precipitated material was removed by filtration. Evaporation of the solvent *in vacuo* and subsequent treatment of the residue with 25 ml of ethyl acetate gave a yellow precipitate, which was collected by filtration and recrystallized from ethanol to give the title compound as white crystals; m.p. 291-293 °C.

25

EXAMPLE 43-Isopropylamino-6-methanesulfonyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

30

a) N-(2-amino-4-(methanesulfonyl)benzenesulfonyl)-N'-isopropylthiourea

A mixture of 2-amino-4-methanesulfonylbenzenesulfonamide (2.5 g), potassium carbonate (1.66 g) and isopropyl isothiocyanate (1.22 g) in 20 ml of dry acetone was heated at 50°C for 18 h. Then the reaction mixture was evaporated in vacuo and the residue was dissolved in 25 ml of water. Then the solution was adjusted to pH 2 by dropwise addition of 4 M HCl at 0 °C with stirring. After stirring for 2 h the product was filtered off and dried, yielding the title compound as white crystals; m.p. 151-153 °C.

b) 3-Isopropylamino-6-methanesulfonyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

10

To a stirred mixture of N-(2-amino-4-(methanesulfonyl)benzenesulfonyl)-N'-isopropylthiourea (3.0 g) and triethylamine (1.7 g) in 30 ml of dry THF at 0 °C was added 5.2 ml of a 20% solution of phosgene in toluene during 5 min. The mixture was stirred at 0 °C for 1 h and then evaporated in vacuo. The white, solid residue was triturated with 50 ml of water for 45 min. and then the product was isolated by filtration. The filter cake was rinsed on the filter with water and dried to give the title compound as white crystals; m.p. > 300 °C.

¹H-NMR(d₆-DMSO), δ (ppm): 10.7 (br, 1H, NH), 7.98-7.72 (m, 3H, arom.), 7.43 (br, 1H, NH), 4.07-3.87 (m, 1H, CH), 3.29 (s, 3H, CH₃), 1.20 (d, 6H, CH₃).

20

EXAMPLE 5

3-Isopropylamino-6-benzenesulfonyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

25 Starting from 2-amino-4-(benzenesulfonyl)benzenesulfonamide and isopropyl isothiocyanate,

and following a procedure analogous to the one described in Example 4a, N-(2-amino-4-(benzenesulfonyl)benzenesulfonyl)-N'-isopropylthiourea was prepared; m.p. 178-180 °C.

Subsequent ring closure with phosgene by a procedure analogous to the one described in Example 4b gave the title compound, m.p. 308-310 °C.

30

EXAMPLE 6

5-Chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Starting from 2-amino-4-methylbenzenesulfonamide and isopropyl isothiocyanate, and
5 following a procedure analogous to the one described in Example 4a, N-(2-amino-3-chlorobenzenesulfonyl)-N'-isopropylthiourea was prepared; m.p. 124-125 °C.

Subsequent ring closure with phosgene by a procedure analogous to the one described in Example 4b gave the title compound; m.p. 204-206 °C.

10

EXAMPLE 73-Isopropylamino-6-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

Starting from 2-amino-4-methylbenzenesulfonamide and isopropyl isothiocyanate, and
15 following a procedure analogous to the one described in Example 4a, N-(2-amino-4-methylbenzenesulfonyl)-N'-isopropylthiourea was prepared, m.p. 137-139 °C.

Subsequent ring closure with phosgene by a procedure analogous to the one described in Example 4b gave the title compound; m.p. 309-311 °C.

20

EXAMPLE 86-Chloro-3-isopropylamino-7-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

Starting from 2-amino-4-chloro-5-methylbenzenesulfonamide and isopropyl isothiocy-
25 anate, and following a procedure analogous to the one described in Example 4a, N-(2-amino-4-chloro-5-methylbenzenesulfonyl)-N'-isopropylthiourea was prepared; m.p. 120-122 °C. Subsequent ring closure with phosgene by a procedure analogous to the one described in Example 4b gave the title compound; ¹H-NMR (d₆-DMSO), δ (ppm): 10.3 (br, 1H, NH), 7.68 (1H, arom.), 7.29 (1H, arom), 7.2 (br, 1H, NH), 4.0-3.8(m, 1H, CH), 2.37 (s, 30 3H, CH₃), 1.20 (d, 6H, CH₃).

EXAMPLE 9

Ethyl (3-Isopropylamino-1,1-dioxo-1,4-dihydro-1 λ ⁶,2,4-benzothiadiazin-6-yl)acetate

Starting from ethyl 3-amino-4-sulfamoylphenylacetate and isopropyl isothiocyanate, and following a procedure analogous to the one described in Example 4a, N-(2-amino-3-
5 (ethoxycarbonylmethyl)benzenesulfonyl)-N'-isopropylthiourea was prepared; m.p. 111-112 °C.

Subsequent ring closure with phosgene by a procedure analogous to the one described in Example 4b gave the title compound; m.p. 182-184 °C; ¹H-NMR (d₆-DMSO), δ (ppm): 10.4 (s, 1H, NH), 7.65-7.57 (1H, arom.), 7.2-7.03 (m, 3H, arom.), 7.03-6.9 (br, 1H, NH), 4.18-
10 4.01 (q, 2H, CH₂), 4.01-3.8 (m, 1H, CH), 3.77 (s, 2H, CH₂), 1.25-1.1 (t+d, 9H, CH₃).

EXAMPLE 10

8-Chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

15 Starting from 2-amino-6-chlorobenzenesulfonamide and isopropyl isothiocyanate, and following a procedure analogous to the one described in Example 4a, N-(2-amino-6-chlorobenzenesulfonyl)-N'-isopropylthiourea was prepared; m.p. 144-146 °C.

Subsequent ring closure with phosgene by a procedure analogous to the one described in
20 Example 4b gave the title compound; m.p. 273-275 °C.

EXAMPLE 11

6-Isopropyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

25 Starting from 2-amino-4-isopropylbenzenesulfonamide and isopropyl isothiocyanate, and following a procedure analogous to the one described in Example 4a, N-(2-amino-4-isopropylbenzenesulfonyl)-N'-isopropylthiourea was prepared. The crude product containing approx. 16 % starting material (by ¹H-nmr) was used without purification for the
30 next step. Subsequent ring closure with phosgene by a procedure analogous to the one described in Example 4b gave the title compound; m.p. 237-239 °C.

EXAMPLE 127-tert-Butyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 5 Starting from 2-amino-5-tert-butylbenzenesulfonamide and isopropyl isothiocyanate, and following a procedure analogous to the one described in Example 4a, N-(2-amino-5-tert-butylbenzenesulfonyl)-N'-isopropylthiourea was prepared; m.p. 128-130 °C. Subsequent ring closure with phosgene by a procedure analogous to the one described in Example 4b gave the title compound; m.p. 290-293 °C.

10

EXAMPLE 133-Isopropylamino-6-phenoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 15 Starting from 2-amino-4-phenoxybenzenesulfonamide and isopropyl isothiocyanate, and following a procedure analogous to the one described in Example 4a, N-(2-amino-4-phenoxybenzenesulfonyl)-N'-isopropylthiourea was prepared. The impure crude product was used without purification. Subsequent ring closure with phosgene by a procedure analogous to the one described in Example 4b gave the title compound; m.p. 250-252 °C.

20

EXAMPLE 146-Hexyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 25 Starting from 2-amino-4-hexylbenzenesulfonamide and isopropyl isothiocyanate, and following a procedure analogous to the one described in Example 4a, N-(2-amino-4-hexylbenzenesulfonyl)-N'-isopropylthiourea was prepared. The crude product was obtained as an oil and used without purification. Subsequent ring closure with phosgene by a procedure analogous to the one described in Example 4b gave the title compound;
- 30 m.p. 319-321 °C.

EXAMPLE 15

6-Cyclohexyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Starting from 2-amino-4-cyclohexylbenzenesulfonamide and isopropyl isothiocyanate, and following a procedure analogous to the one described in Example 4a, N-(2-amino-4-cyclohexylbenzenesulfonyl)-N'-isopropylthiourea was prepared; m.p. 131-133 °C. Subsequent ring closure with phosgene by a procedure analogous to the one described in Example 4b gave the title compound; m.p. 264-266 °C.

EXAMPLE 16

10

6-Chloro-3-(1-ethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

The title compound was prepared from 2-amino-4-chlorobenzenesulfonamide and 3-pentyl isothiocyanate by a method analogous to the one described in Example 4; m.p. 224-226°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 0.88 (t, 6H, 2 x CH₃), 1.33-1.66 (m, 4H, 2 x CH₂), 3.65 (m, 1H, CH), 7.1 (br. s, 1H, NH), 7.21-7.32 (m, 2H, ArH), 7.68 (d, 1H, ArH), 10.30 (br. s, 1H, NH); MS: m/e 301-303 (M⁺); (C₁₂H₁₆N₃ClO₂S₁) calc. C 47.76 H 5.34 N 13.92, found C 47.74 H 5.49 N 13.93.

20

EXAMPLE 17(3-Isopropylamino-1,1-dioxo-1,4-dihydro-1λ⁶,2,4-benzothiadiazin-6-yl)acetic acid

Ethyl (3-isopropylamino-1,1-dioxo-1,4-dihydro-1λ⁶,2,4-benzothiadiazin-6-yl)acetate (0.22 g) was stirred in 5 ml of 4M aqueous sodium hydroxide at room temperature for 1 h. The reaction mixture was then acidified with 4M hydrochloric acid. The resulting precipitate was collected by filtration, the filter cake was rinsed with a small amount of water and dried to give 0.17 g of the title compound, m.p. 262-264 °C.

30

EXAMPLE 186-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)methyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

A mixture of ethyl (3-isopropylamino-1,1-dioxo-1,4-dihydro-1 λ^6 ,2,4-benzothiadiazin-6-yl)acetate (0.20 g), crushed 4Å molecular sieves (0.6 g), cyclopropanecarboxamide oxime (0.30 g), and sodium hydride (40 mg of a 60 % oil dispersion) in 5 ml of dry dimethylformamide was stirred at room temperature for 45 min. Two drops of glacial acetic acid and 20 ml of dichloromethane were added and the mixture was stirred for 10 min. and filtered through celite. The solvents were removed in vacuo from the filtrate. The remaining oil was stirred with 5 ml of water for 15 min and the resulting precipitate was collected by filtration and dried to give the title compound; m.p. 255-259°C.

10

EXAMPLE 19

2-(3-Isopropylamino-1,1-dioxo-1,4-dihydro-1 λ^6 ,2,4-benzothiadiazin-6-yl)acetamide

Ammonia gas was passed through a solution of ethyl (3-isopropylamino-1,1-dioxo-1,4-dihydro-1 λ^6 ,2,4-benzothiadiazin-6-yl)acetate (0.20 g) and sodium cyanide (20 mg) in 10 ml of methanol at room temperature for 5 min. The solution was heated at 55-60 °C in a sealed flask overnight. The solvent was removed in vacuo and the residue was treated with 25 ml of water. On standing, a crystalline precipitate was formed. The crystals were filtered off and dried to give the title compound; m.p. 321-325 °C.

20

EXAMPLE 20

(3-Isopropylamino-1,1-dioxo-1,4-dihydro-1 λ^6 ,2,4-benzothiadiazin-6-yl)acetonitrile

25

A slurry of 2-(3-isopropylamino-1,1-dioxo-1,4-dihydro-1 λ^6 ,2,4-benzothiadiazin-6-yl)acetamide (50 mg) in a mixture of 0.8 ml of acetonitrile, 0.2 ml of formic acid and 25 mg of paraformaldehyde was heated at reflux for 16 h, and then evaporated to dryness. The residue was purified on a silica column eluted with dichloromethane-methanol (95:5) to give the title compound; m.p. 195-203 °C.

30

EXAMPLE 21

3-Benzoyloxyamino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide

To a solution of O-benzylhydroxylamine hydrochloride (500 mg) and triethylamine (200 mg) in ethanol (10 ml) was added 3,7-dichloro-4H-1,2,4-benzothiadiazine 1,1-dioxide (500 mg). The mixture was stirred for 3 h and concentrated *in vacuo*. The crude product was taken up in hot ethyl acetate (50 ml) and cooled to room temperature and the precipitate was collected by filtration to give the title compound (200 mg, 59 %); m.p. >220 °C; ¹H-NMR (DMSO-d₆) ppm; 11.2 (br s, 1H, NH), 7.7-7.35(m, 9H, arom. and NH), 4.49 (s, 2H, CH₂). Analysis: C₁₄H₁₂ClN₃O₃S requires C 49.78, H 3.58, N 12.44 (found C 49.49, H 3.80, N 12.09).

EXAMPLE 227-Chloro-3-methoxyamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Starting from 3,7-dichloro-4H-1,2,4-benzothiadiazine 1,1-dioxide (502 mg; 2 mmol) and O-methylhydroxylamine hydrochloride (300 mg) and with the use of the same procedure as in example 21, 280 mg (57 %) of the title compound was prepared; m.p. >220 °C; ¹H-NMR (DMSO-d₆) ppm; 11.35 (s, 1H, NH), 11.28 (s, 1H, NH), 7.78 (d, 1H, H-8), 7.63 (dd, 2H, H-6 and H-5), 3.80 (s, 3H, CH₃); ¹³C-NMR (DMSO-d₆) ppm; 151.19, 132.79, 131.26, 127.10, 123.00, 120.83, 118.78, 63.25.

EXAMPLE 23

25

6-Chloro-3-butylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

The title compound was prepared from 2-amino-4-chlorobenzenesulfonamide and butyl isothiocyanate by a method analogous to the one described in Example 4; m.p. 267-269 °C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 0.90 (t, 3H, CH₃), 1.24-1.60 (m, 4H, CH₂CH₂), 3.21 (q, 2H, NHCH₂), 7.2-7.4 (m, 3H, ArH + NH), 7.68 (d, 1H, ArH), 10.55 (br. s, 1H, NH); MS: m/e 287-289 (M⁺); (C₁₁H₁₄N₃ClO₂S₁) calc. C 45.91 H 4.91 N 14.60, found C 45.92 H 5.12 N 14.46.

EXAMPLE 246-Chloro-3-hexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

5

The title compound was prepared from 2-amino-4-chlorobenzenesulfonamide and hexyl isothiocyanate by a method analogous to the one described in Example 4; m.p. 244-247°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 0.88 (distorted t, 3H, CH₃), 1.31 (m, 6H, 3 x CH₂), 1.53 (m, 2H, CH₂), 3.22 (q, 2H, NHCH₂), 7.2-7.4 (m, 3H, ArH + NH), 7.68 (d, 1H, ArH), 10.55 (br.s, 1H, NH); MS: m/e 315/317 (M⁺); (C₁₃H₁₈N₃ClO₂S₁) calc. C 49.44 H 5.74 N 13.31, found C 49.59 H 6.01 N 13.25.

EXAMPLE 2515 7-Bromo-3-isopropylamino-6-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

A solution of 3-isopropylamino-6-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide (307 mg; 1 mmol) in water (5ml) was added 40% hydrobromic acid (0.44 ml; 3 mmol). The solution was then heated to 70 °C and 30% hydrogen peroxide (0.33 g; 3 mmol) was added. After 30 min the reaction mixture was cooled and extracted with ethyl acetate (20 ml) and purified by column chromatography (ethyl acetate: ethanol 9: 1). Concentration of the appropriate fractions produced the title compound (22 mg); ¹H-NMR (DMSO-d₆) ppm; 7.60 (s, 1H), 7.10 (s, 1H), 6.65 (s, 1H), 3.95 (m, 1H) 1.11 (d, 6H).

25

EXAMPLE 266,7-Dichloro-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

30 The title compound was prepared from 2-amino-4,5-dichlorobenzenesulfonamide and 1,2-dimethylpropyl isothiocyanate by a method analogous to the one described in Example 4; m.p. 242-250°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 0.90 (d, 3H, CH₃), 0.91 (d, 3H, CH₃), 1.10 (d, 1H, CH₃), 1.77 (m, 1H, CH(CH₃)₂), 3.71 (m, 1H, NHCH), 7.29 (br., 1H, NH),

7.49 (br. s, 1H, ArH), 7.89 (s, 1H, ArH), 10.41 (br.s, 1H, NH); MS: m/e 335/337/339 (M+); (C₁₂H₁₅N₃Cl₂O₂S₁) calc. C 42.87 H 4.50 N 12.50, found C 42.94 H 4.68 N 12.45.

EXAMPLE 27

5

6-Chloro-3-(1,2,2-trimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Starting from 3,6-dichloro-4H-1,2,4-benzothiadiazine 1,1-dioxide (500 mg; 1.99 mmol) and 1,2,2-trimethylpropylamine (500 mg; 5.62 mmol) with the use of same procedure as in
-10 example 21 250 mg (39.8 %) of the title compound was prepared; m.p. >220 °C; ¹H-NMR (DMSO-d₆) ppm; 10.3 (s, 1H, NH), 7.70 (d, 1H, H-8), 7.31 (dd, 1H, H-7), 7.25 (br d, 1H, H-5), 7.15 (br, 1H, NH), 3.75 (q, 1H, CH), 1.10 (d, 3H, CH₃), 0.9 (s, 9H, 3xCH₃). Analysis: C₁₃H₁₈ClN₃O₂S requires C 49.44 , H 5.74 , N 13.3 (found C 49.37 , H 6.04 , N 13.11).

15

EXAMPLE 28

7-Bromo-3-(1,2,2-trimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Starting from 7-bromo-3-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide (300 mg; 1.01
20 mmol) and 1,2,2-trimethylpropylamine (359 mg; 4.04 mmol) with the use of same procedure as in example 21 200 mg (54.9 %) of the title compound was prepared; m.p. >220 °C; ¹H-NMR (DMSO-d₆) ppm; 10.35 (s, 1H, NH), 7.78 (d, 1H, H-8), 7.6 (dd, 1H, H-6), 7.12 (br d, 1H, H-5), 6.95 (br, 1H, NH), 3.72 (q, 1H, CH), 1.10 (d, 3H, CH₃), 0.92 (s, 9H, 3xCH₃); MS:EI/70eV: 361 (M+1), 304, 277, 236, 170, 116, 90, 44.

25

EXAMPLE 29

6,7-Dichloro-3-(1-methylbutyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

30 The title compound was prepared from 2-amino-4,5-dichlorobenzenesulfonamide and 2-pentyl isothiocyanate by a method analogous to the one described in Example 4; m.p. 217-220°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 0.90 (t, 3H, CH₃), 1.14 (d, 3H, CH₃), 1.20-1.55 (m, 4H, CH₂CH₂), 3.83 (m, 1H, NHCH), 7.33 (br., 1H, NH), 7.49 (br. s, 1H, ArH), 7.89

(s, 1H, ArH), 10.48 (br.s, 1H, NH); MS: m/e 335/337/339 (M+).

EXAMPLE 30

5 5-Amino-7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

To a stirred suspension of 7-chloro-3-isopropylamino-5-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide (200 mg; 0.63 mmol) and zinc (200 mg; 3.06 mmol) in acetic acid (20 ml) was added 36 % hydrochloric acid (0.3 ml). The mixture was stirred for 12 hr. After filtration
10 and concentration in vacuo the crude product was purified by column chromatography eluting with ethyl acetate : ethanol (9:1). Concentration of the appropriate fractions produced 90 mg of the title compound; m.p. > 230 °C.

EXAMPLE 31

15

7-Chloro-3-(1,3-dimethylpentyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Starting from 3,7-dichloro-4H-1,2,4-benzothiadiazine 1,1-dioxide (500 mg; 1.99 mmol) and 1,3-dimethylpentylamine (1 g; 8.68 mmol) and with the use of same procedure as in
20 example 21 230 mg (35.1 %) of the title compound was prepared; m.p. >220 °C; ¹H-NMR (DMSO-d₆) ppm; 10.41 (s, 1H, NH), 7.68 (d, 1H, H-8), 7.60 (dd, 1H, H-5), 7.2 (d, 1H, H-7), 7.0 (br, 1H, NH), 3.95 (m, 1H, CH), 1.5 (m, 8H), 0.9 (m, 6H, 2xCH₃); MS: EI/70eV: 329 (M⁺), 301, 258, 231, 190, 126, 69, 44. Analysis: C₁₄H₂₀ClN₃O₂S requires C 50.98, H 6.11, N 12.74 (found C 51.23, H 6.42, N 12.53).

25

EXAMPLE 32

7-Chloro-3-(1,5-dimethylhexyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

30 Starting from 3,7-dichloro-4H-1,2,4-benzothiadiazine 1,1-dioxide (300 mg; 1.19 mmol) and 1,5-dimethylhexylamine (1 g; 7.73 mmol) and with the use of same procedure as in example 21 260 mg (63.5 %) of the title compound was prepared; m.p. >220 °C; ¹H-NMR (DMSO-d₆) ppm; 10.50 (s, 1H, NH), 7.68 (d, 1H, H-8), 7.63 (dd, 1H, H-5), 7.25 (d, 1H, H-

7), 7.1 (br, 1H, NH), 3.85 (q, 1H, CH), 1.5 (m, 4H), 1.35 (m, 3H), 1.15 (d, 3H, CH₃), 0.85 (d, 6H, 2xCH₃).

MS:EI/70eV: 343 (M⁺), 300, 258, 231, 190, 126, 69, 44.

5

EXAMPLE 33

7-Chloro-3-(1,4-dimethylpentyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 10 Starting from 3,7-dichloro-4H-1,2,4-benzothiadiazine 1,1-dioxide (300 mg; 1.19 mmol) and 1,4-dimethylpentylamine (1.0 g; 8.68 mmol) with the use of same procedure as in example 21 210 mg (53.5 %) of the title compound was prepared; m.p. >220 °C; ¹H-NMR (DMSO-d₆) ppm; 10.4 (s, 1H, NH), 7.7 (d, 1H, H-8), 7.6 (dd, 1H, H-5), 7.25 (d, 1H, H-7), 7.1 (br, 1H, NH), 3.88 (q, 1H, CH₂), 1.55 (m, 3H), 1.21 (m, 2H), 1.1 (d, 3H, CH₃), 0.9 (d, 6H, 2xCH₃); MS:EI/70eV: 330 (M⁺), 258, 231, 190, 126, 69, 55, 44. Analysis: C₁₀H₁₂ClN₃O₂S requires C 50.98, H 6.11, N 12.74 (found C 51.14, H 6.43, N 12.64)
- 15

20

EXAMPLE 34

5,7-Dichloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

- Starting from 2-amino-3,5-dichlorobenzenesulfonamide (0.5 g; 2.07 mmol) and isopropyl isothiocyanate (251 mg; 2.48 mmol) with the use of the procedure described in example 4, 25 100 mg (17.4 %) of the title compound was isolated; m.p. >230 °C

EXAMPLE 35

7-Chloro-3-(3,3-diphenylpropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide

Starting from 3,7-dichloro-4H-1,2,4-benzothiadiazine 1,1-dioxide (300 mg; 1.19 mmol) and 3,3-diphenylpropylamine (1.5 g; 7.1 mmol) with the use of same procedure as in example

21 300 mg (59 %) of the title compound was prepared; ¹H-NMR (DMSO-d₆) ppm; 10.7 (s, 1H, NH), 7.68 (d, 1H, H-8), 7.60 (dd, 1H, H-5), 7.25 (m, 11H,), 4.1 (t, 1H, CH), 3.11 (q, 2H, CH₂), 2.35 (q, 2H, CH₂); MS:EI/70eV: 425 (M⁺), 245, 193, 180, 165, 152, 115.

5

EXAMPLE 367-Chloro-3-(4-phenylbutylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide

Starting from 3,7-dichloro-4H-1,2,4-benzothiadiazine 1,1-dioxide (300 mg; 1.19 mmol) and
10 4-phenylbutylamine (1.5 g; 4.12 mmol) and with the use of same procedure as in example
21 120 mg (27.7 %) of the title compound was prepared.; ¹H-NMR (DMSO-d₆) ppm; 10.8 (s, 1H, NH), 7.75 (d, 1H, H-8), 7.60 (dd, 1H, H-5), 7.2 (m, 7H), 3.29 (t, 2H, CH₂), 2.66 (t, 2H, CH₂), 1.5 (m, 4H, 2xCH₂); MS:EI/70eV: 363 (M⁺), 272, 259, 231, 180, 91, 44.

15

EXAMPLE 376-Chloro-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Phosphorus pentoxide (7.55 g, 53.2 mmol), N,N-dimethylcyclohexylamine (17 ml, 113
20 mmol) and 1,2-dimethylpropylamine hydrochloride (12.4 g, 100.4 mmol) were carefully
mixed and heated with mechanical stirring on an oil bath at 190-200°C for about 15 min.
To the homogeneous mass was added 6-chloro-3,4-dihydro-3-oxo-1,2,4-benzothiadiazine
1,1-dioxide (5.84 g, 25.1 mmol) and the mixture was stirred at 235°C for 2 h. After cooling
to about 100°C, water (200 ml) was added and the dark mixture was hydrolysed by stirring
25 over night at room temperature. The precipitate was isolated by filtration and recrystallised
from ethanol with decolorising charcoal to give 2.83 g (37%) of the pure title compound;
m.p.(DSC) 264.7°C; ¹H-NMR (DMSO-d₆): δ 0.90 (dd, 6H, CH(CH₃)₂), 1.09 (d, 3H,
NCHCH₃), 1.76 (m, 1H, CH(CH₃)₂), 3.70 (m, 1H, NHCH), 7.15 (br., 1H, NH), 7.28 (m, 2H,
ArH), 7.68 (d, 1H, ArH), 10.3 (br. s, 1H, NH); (C₁₂H₁₆N₃ClO₂S₁) calc. C 47.76 H 5.34 N
30 13.92, found C 47.66 H 5.47 N 13.91.

EXAMPLE 38

6-Chloro-3-(1,2-dimethylpropyl)amino-7-sulfamoyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

The title compound was prepared from 6-chloro-2,3-dihydro-3-oxo-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide (4.94 g, 15.84 mmol) and 1,2-dimethylpropylamine hydrochloride (8.0 g, 65.0 mmol) by a method analogous to the method described in example 37, except that the product was purified by column chromatography affording 143 mg (2.4%) of pure product; m.p.(DSC) 244°C (methanol); ¹H-NMR (DMSO-d₆): δ 0.90 (dd, 6H, CH(CH₃)₂), 1.11 (d, 3H, NCHCH₃), 1.76 (m, 1H, CH(CH₃)₂), 3.71 (m, 1H, NHCH), 7.34 (br., 1H, NH), 7.41 (br.s, 1H, ArH), 7.80 (br.s, 2H, SO₂NH₂), 8.18 (s, 1H, ArH), 10.58 (br.s, 1H, NH); MS (FAB): m/e 381/383 (MH⁺); (C₁₂H₁₇N₄ClO₄S₂) calc. C 37.84 H 4.50 N 14.71, found C 37.66 H 4.65 N 14.52.

EXAMPLE 393-Anilino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide

The title compound was prepared from 6-chloro-2,3-dihydro-3-oxo-1,2,4-benzothiadiazine 1,1-dioxide (3.0 g, 12.9 mmol) and aniline (4.8 g, 52.0 mmol) by a method analogous to the method described in example 37, except that triethylamine hydrochloride (7.1 g, 52.0 mmol) was used instead of N,N-dimethylcyclohexylamine. Yield 1.68 g (44 %) of pure product; m.p.(DSC) >350°C (ethanol); ¹H-NMR (DMSO-d₆): δ 7.1-7.8 (m, 8H, ArH), 9.5 (br.s, 1H, NH), 11.05 (br.s, 1H, NH); MS: m/e 307/309 (M⁺); (C₁₃H₁₀N₃ClO₂S₁) calc. C 50.74 H 3.28 N 13.65, found C 50.31 H 3.24 N 13.59.

EXAMPLE 407-Chloro-3-(4-pyridyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

The title compound was prepared from 6-chloro-2,3-dihydro-3-oxo-1,2,4-benzothiadiazine 1,1-dioxide (3.0 g, 12.9 mmol) and 4-aminopyridine (4.9 g, 52.0 mmol) by a method analogous to the method described in example 39, except that the hydrolysed mixture was adjusted to pH 7 and extracted with ethyl acetate (5 x 50 ml). The organic phase was

evaporated to dryness and the residue was purified by column chromatography affording 34 mg (0.9%) of product; ¹H-NMR (DMSO-d₆): δ 7.32 (d, 1H, ArH), 7.40-7.52 (m, 4H, ArH), 7.68 (dd, 1H, ArH), 7.76 (dd, 1H, ArH), 9.6 (br.s, 1H, NH), 11.05 (br s, 1H, NH).

5

EXAMPLE 416-Chloro-3-isobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

A mixture of 2-amino-4-chlorobenzenesulfonamide (5.0 g, 24.18 mmol) and isobutyl isothiocyanate (10 ml, 83.6 mmol) was heated at 150°C for 3 h. The mixture was allowed to cool and then stirred with 50 ml of ethyl acetate for 30 min. The precipitate was isolated by filtration and recrystallised from ethanol to give 2.9 g (42 %) of the pure title compound; m.p.298-301°C; ¹H-NMR (DMSO-d₆): δ 0.91 (d, 6H, CH(CH₃)₂), 1.83 (m, 1H, CH(CH₃)₂), 3.05 (t, 2H, CH₂), 7.2-7.4 (m, 3H, ArH + NH), 7.67 (d, 1H, ArH), 10.5 (br.s, 1H, NH); MS: m/e 287/289 (M⁺); (C₁₁H₁₄N₃ClO₂S₁) calc. C 45.91 H 4.90 N 14.60, found C 45.90 H 5.04 N 14.66.

15

EXAMPLE 4220 3-sec-Butylamino-6-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide

A mixture of 2-amino-4-chlorobenzenesulfonamide (2.1 g, 10.16 mmol) and sec-butyl isothiocyanate (5.0 ml, 40.9 mmol) was heated at 150°C for 4 h. The mixture was allowed to cool and then stirred with 25 ml of ethyl acetate for 1 h. The precipitate was isolated by filtration and recrystallised from ethanol to give 201 mg (7 %) of the title compound as white crystals; m.p.242-245°C; ¹H-NMR (DMSO-d₆): δ 0.89 (t, 3H, CH₂CH₃), 1.15 (d, 3H, CHCH₃), 1.50 (m, 2H, CH₂), 3.76 (m, 1H, CH), 7.19 (br. s, 1H, NH), 7.29 (m, 2H, ArH), 7.68 (d, 1H, ArH), 10.35 (br.s, 1H, NH); MS: m/e 287/289 (M⁺); (C₁₁H₁₄N₃ClO₂S₁) calc. C 45.91 H 4.90 N 14.60, found C 46.42 H 5.08 N 14.65.

25

30

EXAMPLE 436-Chloro-3-cyclohexylmethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

A mixture of 2-amino-4-chlorobenzenesulfonamide (2.1 g, 10.16 mmol) and cyclohexylmethyl isothiocyanate (6.31 g, 40.6 mmol) was heated at 150°C for 4 h. The mixture was allowed to cool and then stirred with 25 ml of ethyl acetate for 1 h. The precipitate was isolated by filtration and recrystallised from ethanol to give 867 mg (26 %) of the title compound; m.p. 317-323°C; ¹H-NMR (DMSO-d₆): δ 0.8-1.8 (m, 11H, cyclohexyl), 3.08 (t, 2H, CH₂), 7.78 (m, 3H, ArH + NH), 7.68 (d, 1H, ArH), 10.52 (br.s, 1H, NH); MS: m/e 327/329 (M⁺); (C₁₄H₁₈N₃ClO₂S₁) calc. C 51.29 H 5.53 N 12.82, found C 51.21 H 5.72 N 12.81.

10

EXAMPLE 44

6-Fluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

A mixture of 2-amino-4-fluorobenzenesulfonamide (1.9 g, 10 mmol) and isopropyl isothiocyanate (6.4 ml, 60 mmol) was heated at 140°C for 2.5 h. The mixture was cooled to room temperature and stirred with 50 ml of ethyl acetate for 20 min. The precipitate was isolated by filtration and washed with ethyl acetate to give 355 mg (14 %) of the title compound; m.p. 266-269°C; ¹H-NMR (DMSO-d₆): δ 1.18 (d, 6H, CH(CH₃)₂), 3.91 (m, 1H, CH(CH₃)₂), 7.00-7.13 (m, 2H, ArH), 7.16 (br. s, 1H, NH), 7.73 (dd, 1H, ArH), 10.4 (br.s, 1H, NH); MS: m/e 257 (M⁺, 25%); (C₁₀H₁₂N₃F₁O₂S₁) calc. C 46.68 H 4.70 N 16.33, found C 46.84 H 4.88 N 16.13.

20

EXAMPLE 45

25

3-Cyclopentylamino-6-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide

A mixture of 2-amino-4-fluorobenzenesulfonamide (1.71 g, 9 mmol) and cyclopentyl isothiocyanate (4.6 ml, 36 mmol) was heated at 140°C for 4 h. The mixture was cooled to room temperature and stirred with 50 ml of ethyl acetate. The precipitate was isolated by filtration and recrystallised from ethanol to give 591 mg (23 %) of the title compound; m.p. 295-298°C; ¹H-NMR (DMSO-d₆): δ 1.37-2.02 (m, 8H, cyclopentyl), 4.05 (sext, 1H, CH).

30

6.97-7.15 (m, 2H, ArH), 7.32 (br. s, 1H, NH), 7.72 (dd, 1H, ArH), 10.35 (br.s, 1H, NH); MS: m/e 283 (M⁺, 21%); (C₁₂H₁₄N₃F₁O₂S₁) calc. C 50.87 H 4.98 N 14.83, found C 50.75 H 5.12 N 14.93.

5

EXAMPLE 467-Chloro-3-isopropylamino-5-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide

The title compound was prepared from 2-amino-5-chloro-3-nitrobenzenesulfonamide and isopropyl isothiocyanate by a method analogous to the one described in Example 4; m.p.266-267°C; ¹H-NMR (DMSO-d₆): δ 1.20 (d, 6H, CH(CH₃)₂), 3.92 (m, 1H, CH(CH₃)₂), 8.19 (d, 1H, ArH), 8.48 (d, 1H, ArH), 8.72 (br. s, 1H, NH), 10.57 (br.s, 1H, NH); MS: m/e 318/320 (M⁺); (C₁₀H₁₁N₄Cl₁O₄S₁) calc. C 37.68 H 3.48 N 17.58, found C 37.82 H 3.54 N 17.58.

15

EXAMPLE 473-tert-Butylamino-6-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide

20

The title compound was prepared from 2-amino-4-chlorobenzenesulfonamide and *tert*-butyl isothiocyanate by a method analogous to the one described in Example 4 except that the mixture was heated at 60°C for 6 days. The intermediate N-(2-amino-4-chlorobenzenesulfonyl)-N'-*tert*-butylthiourea and the ring closed product were both purified by column chromatography; m.p.291-294°C (light petroleum/ ethyl acetate); ¹H-NMR (DMSO-d₆): δ 1.39 (s, 9H, C(CH₃)₃), 6.92 (br s, 1H, NH), 7.17 (d, 1H, ArH), 7.28 (dd, 1H, ArH), 7.68 (d, 1H, ArH), 10.25 (br.s, 1H, NH); MS: m/e 287/289 (M⁺).

30

EXAMPLE 487-Iodo-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

The title compound was prepared from 2-amino-5-iodobenzenesulfonamide and isopropyl

isothiocyanate by a method analogous to the one described in Example 4; m.p.305-307°C dec; ¹H-NMR (DMSO-d₆): δ 1.17 (d, 6H, CH(CH₃)₂), 3.91 (m, 1H, CH(CH₃)₂), 7.02 (d, 1H, ArH), 7.15 (br., 1H, NH), 7.8-7.9 (m, 2H, ArH), 10.43 (br.s, 1H, NH); MS: m/e 365 (M+, 27%); (C₁₀H₁₂N₃I₁O₂S₁) calc. C 32.89 H 3.31 N 11.51, found C 32.79 H 3.41 N 11.27.

5

EXAMPLE 49

6-Chloro-7-fluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

10 The title compound was prepared from 2-amino-4-chloro-5-fluorobenzenesulfonamide and isopropyl isothiocyanate by a method analogous to the one described in Example 4; m.p.282-285°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 1.17 (d, 6H, CH(CH₃)₂), 3.92 (m, 1H, CH(CH₃)₂), 7.34 (br., 1H, NH), 7.45 (d, 1H, ArH), 7.76 (d, 1H, ArH), 10.44 (br.s, 1H, NH); MS: m/e 291/293 (M+); (C₁₀H₁₁N₃Cl₁F₁O₂S₁) calc. C 41.17 H 3.80 N 14.40, found C
15 41.3 H 3.8 N 14.4.

EXAMPLE 50

20 3-Isopropylamino-6-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

The title compound was prepared from 2-amino-4-trifluoromethylbenzenesulfonamide and isopropyl isothiocyanate by a method analogous to the one described in Example 4; m.p.294-297°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 1.20 (d, 6H, CH(CH₃)₂), 3.95 (m,
25 1H, CH(CH₃)₂), 7.42 (br., 1H, NH), 7.56 (m, 2H, ArH), 7.99 (d, 1H, ArH), 10.55 (br.s, 1H, NH); MS: m/e 307 (M+, 33%); (C₁₁H₁₂N₃F₃O₂S₁·H₂O) calc. C 40.6 H 4.3 N 12.9, found C 41.0 H 4.1 N 13.1.

EXAMPLE 51

30

7-Chloro-3-cyclopropylmethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

The title compound was prepared from 2-amino-5-chlorobenzenesulfonamide and

cyclopropylmethyl isothiocyanate by a method analogous to the one described in Example 4; m.p.288-290°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 0.20-0.54 (m, 4H, CH₂CH₂), 1.05 (m, 1H, CH), 3.10 (distorted t, 1H, NHCH₂), 7.22 (d, 1H, ArH), 7.31 (br., 1H, NH), 7.55-7.69 (m, 2H, ArH), 10.7 (br.s, 1H, NH); MS: m/e 285/287 (M⁺); (C₁₁H₁₂N₃Cl₁O₂S₁) calc. C 46.24 H 4.23 N 14.71. found C 46.48 H 4.32 N 14.72.

EXAMPLE 52

3-Isopropylamino-7-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

10

The title compound was prepared from 2-amino-5-methylbenzenesulfonamide and isopropyl isothiocyanate by a method analogous to the one described in Example 4; m.p.266-268°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 1.16 (d, 6H, CH(CH₃)₂), 3.91 (m, 1H, CH(CH₃)₂), 6.92 (br.d, 1H, NH), 7.06 (d, 1H, ArH), 7.35 (dd, 1H, ArH), 7.45 (d, 1H, ArH), 10.20 (br.s, 1H, NH); MS: m/e 253 (M⁺, 44%); (C₁₁H₁₅N₃O₂S₁) calc. C 52.16 H 5.97 N 16.59, found C 52.28 H 6.19 N 16.49.

EXAMPLE 53

20

5,7-Dibromo-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

The title compound was prepared from 2-amino-3,5-dibromobenzenesulfonamide and isopropyl isothiocyanate by a method analogous to the one described in Example 4; m.p.306-311°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 1.19 (d, 6H, CH(CH₃)₂), 3.90 (m, 1H, CH(CH₃)₂), 7.82 (d, 1H, ArH), 7.92 (br.d, 1H, NH), 8.16 (d, 1H, ArH), 9.65 (br.s, 1H, NH); MS: m/e 395/397/399 (M⁺); (C₁₀H₁₁N₃Br₂O₂S₁) calc. C 30.25 H 2.79 N 10.58, found C 30.34 H 2.77 N 10.48.

30

EXAMPLE 54

6-Acetyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

The title compound was prepared from 4-acetyl-2-aminobenzenesulfonamide and isopropyl isothiocyanate by a method analogous to the one described in Example 4; m.p. 305-308°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 1.19 (d, 6H, CH(CH₃)₂), 3.95 (m, 1H, CH(CH₃)₂), 7.25 (br., 1H, NH), 7.70-7.85 (m, 3H, ArH), 10.5 (br.s, 1H, NH); MS: m/e 281 (M⁺, 39%); (C₁₂H₁₅N₃O₃S₁) calc. C 51.23 H 5.37 N 14.94, found C 51.15 H 5.50 N 14.69

EXAMPLE 55

3-Allylamino-6-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide

The title compound was prepared from 2-amino-4-chlorobenzenesulfonamide and allyl isothiocyanate by a method analogous to the one described in Example 4; m.p. 284-286°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 3.88 (distorted t, 2H, NHCH₂), 5.1-5.3 (m, 2H, =CH₂), 5.78-6.0 (m, 1H, =CH), 7.22-7.35 (m, 2H, ArH), 7.50 (br. t, 1H, NH), 7.69 (d, 1H, ArH), 10.73 (br.s, 1H, NH); MS: m/e 271/273 (M⁺); (C₁₀H₁₀N₃Cl₁O₂S₁) calc. C 44.20 H 3.71 N 15.46, found C 44.10 H 3.79 N 15.32.

EXAMPLE 56

3-Isopropylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide

25 a) 2-Chloro-5-nitrobenzenesulfonamide

Glacial acetic acid (160 mL) was saturated with gaseous sulfur dioxide and then supplemented with an aqueous solution of cupric chloride (7 g/20 mL).

A solution of 2-chloro-5-nitroaniline (10 g) in glacial acetic acid (160 mL) and 12N HCl (40 mL) was cooled to -5°C. A solution of sodium nitrite (4 g) in water (20 mL) was then added dropwise under stirring to the cold solution of 2-chloro-5-nitroaniline.

The diazonium salt formed was added under stirring to the cold solution of sulfur dioxide in acetic acid previously prepared. After 10 min., the mixture was poured on ice (200 g). The

resulting precipitate was collected by filtration, washed with water and suspended in a 10% aqueous solution of ammonia (200 mL). After stirring at room temperature for 30 min., the mixture was concentrated to the half volume by evaporation under reduced pressure. The resulting suspension was adjusted to pH 1 with 12N HCl. The insoluble material was collected by filtration, washed with water and crystallized from methanol-water to give 8.8 g of the title compound; m.p. 174-176°C.

b) 2-Amino-5-nitrobenzenesulfonamide

10 A suspension of 2-chloro-5-nitrobenzenesulfonamide (8 g) in concentrated aqueous ammonia (80 mL) was saturated with ammonia just before its introduction into a sealed vessel. The former was placed in an autoclave and heated at 120°C for 5 h. The reaction mixture was then concentrated to the half volume by evaporation under reduced pressure and the resulting precipitate was collected by filtration, washed with water and dried to
15 give the title compound (yield: 6.1 g); m.p. 202-204°C.

c) 3-(Imidazol-1-yl)-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide imidazolium salt

20 To a hot solution of 2-amino-5-nitrobenzenesulfonamide (5 g) in dioxane (150 mL) was added thiocarbonyldiimidazole (14 g) and the reaction mixture was refluxed for 5 h. After cooling, the precipitate of the title compound was collected by filtration, washed with dioxane and dried to give the title compound (yield 5.7 g); m.p. 246-248°C.

25

d) 3-Isopropylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide

3-(Imidazol-1-yl)-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide imidazolium salt was treated with isopropylamine according to the general procedure Method A to give the title
30 compound;

m.p. 311-313 °C; IR (KBr): 3363, 3221, 2980, 1657, 1646, 1615, 1601, 1572, 1532, 1494, 1339, 1284, 1267, 1155, 1106 cm⁻¹; ¹H-NMR (DMSO-d₆, HMDS; δ ppm): 1.10 (d, 6H, 2 x

CH₃), 3.90 (m, 1H, NH-CH), 7.35 (m, 2H, 5-H + NH-CH), 8.35 (m, 2H, 6-H + 8-H), 10.90 (bs, 1H, NH).

EXAMPLE 57

5

3-sec-Butylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide

3-(Imidazol-1-yl)-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide imidazolium salt was treated with sec-butylamine according to the general procedure Method A to give the title compound; m.p. 287-288°C.

EXAMPLE 58

15

3-(1,2-Dimethylpropyl)amino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide

3-(Imidazol-1-yl)-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide imidazolium salt was treated with 1,2-dimethylpropylamine according to the general procedure Method B to give the title compound; m.p. 308-311°C; IR (KBr): 3294, 3199, 3101, 2965, 1636, 1600, 1566, 1538, 1497, 1485, 1349, 1252, 1166, 1153, 1107 cm⁻¹.

20

EXAMPLE 59

3-(Cyclopropylmethyl)amino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide

3-(Imidazol-1-yl)-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide imidazolium salt was treated with cyclopropylmethylamine according to the general procedure Method D to give the title compound; m.p.: 276-278°C; IR (KBr): 3290, 3193, 3104, 2994, 1635, 1603, 1564, 1539, 1499, 1486, 1347, 1276, 1251, 1153, 1111 cm⁻¹.

30

EXAMPLE 60

7-Nitro-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

3-(Imidazol-1-yl)-7-nitro-4*H*-1,2,4-benzothiadiazine 1,1-dioxide imidazolium salt was treated with propylamine according to the general procedure Method A to give the title compound; m.p. 268-270°C.

5

EXAMPLE 61

3-Cyclobutylamino-7-nitro-4*H*-1,2,4-benzothiadiazine 1,1-dioxide

10 3-(Imidazol-1-yl)-7-nitro-4*H*-1,2,4-benzothiadiazine 1,1-dioxide imidazolium salt was treated with cyclobutylamine according to the general procedure Method D to give the title compound; m.p. 298-301°C.

EXAMPLE 62

15

7-Amino-3-isopropylamino-4*H*-1,2,4-benzothiadiazine 1,1-dioxide

A solution of 3-isopropylamino-7-nitro-4*H*-1,2,4-benzothiadiazine 1,1-dioxide (0.6 g) in hot methanol (25 mL) was supplemented with 10% Pd/C (0.06 g) and submitted to hydrogen
20 under pressure (4 bars) for 1 h at 40°C. The insoluble material was removed by filtration and the filtrate was concentrated to dryness by evaporation under reduced pressure. The residue of the crude title compound was recrystallized from methanol-water (yield: 0.45 g); m.p.: 278-283°C; IR (KBr): 3455, 3363, 3216, 2972, 1618, 1575, 1510, 1298, 1255, 1174, 1146, 1113 cm⁻¹; ¹H-NMR (DMSO-d₆, HMDS; δ ppm): 1.10 (d, 6H, 2 x CH₃), 3.85 (m, 1H, NH-CH), 5.15 (bs, 2H, NH₂), 6.50-6.95 (bm, 4H, 5-H + 6-H + 8-H + NH-CH), 9.75 (bs, 1H, NH).

EXAMPLE 63

30 7-Acetylamino-3-isopropylamino-4*H*-1,2,4-benzothiadiazine 1,1-dioxide

A mixture of 7-amino-3-isopropylamino-4*H*-1,2,4-benzothiadiazine 1,1-dioxide (0.18 g) and

acetic anhydride (0.6 mL) in dioxane (2 mL) was stirred for 1 h at room temperature. The medium was then mixed with water (5 mL) and stirred for 1 h. The solvents were removed by distillation under reduced pressure and the residue of the crude title compound was recrystallized from methanol-water to give the title compound (yield: 0.16 g); m.p. 260-
5 262°C; IR (KBr): 3353, 3316, 3240, 3101, 3069, 2974, 1672, 1624, 1608, 1581, 1546, 1497, 1467, 1391, 1279, 1159, 1142, 1123, 1104 cm⁻¹; ¹H-NMR (DMSO-d₆, HMDS; δ ppm): 1.10 (d, 6H, 2 x CH₃), 2.00 (s, 3H, COCH₃), 3.90 (m, 1H, NH-CH), 6.85 (bd, 1H, NH-CH), 7.05 (d, 1H, 5-H), 7.60 (bd, 1H, 6-H), 8.00 (bs, 1H, 8-H), 10.00 (bs, 1H, CONH), 10.10 (bs, 1H, NH).

10

EXAMPLE 64

6,7-Dichloro-3-hexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

15

a) 6,7-Dichloro-3-(imidazol-1-yl)-4H-1,2,4-benzothiadiazine 1,1-dioxide monohydrate

A mixture of 2-amino-4,5-dichlorobenzenesulfonamide (10 g) and thiocarbonyldiimidazole (22 g) in dioxane (160 mL) was refluxed for 2-3 h. The solvent was removed by distillation
20 under reduced pressure and the residue was dispersed in water (100 mL). The addition of an aqueous solution of NaOH (16 g/160 mL) gave a solution which, after cooling, abundantly precipitated the crystalline sodium salt of the title compound. The salt was collected by filtration and dissolved in a 1:2 mixture of methanol and water (300 mL), treated with charcoal, filtered, and the filtrate was adjusted to pH 2 with 12N HCl. The
25 precipitate was collected by filtration, washed with water and dried (yield: 11.3 g); m.p.: 312-315°C.

b) 6,7-Dichloro-3-hexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

30 6,7-Dichloro-3-(imidazol-1-yl)-4H-1,2,4-benzothiadiazine 1,1-dioxide monohydrate was treated with hexylamine according to the general procedure Method B to give the title compound; m.p. 282-286°C; IR (KBr): 3332, 3173, 3074, 2956, 2930, 2854, 1637, 1580,

1562, 1464, 1241, 1168, 1143, 1132 cm^{-1} .

EXAMPLE 65

5 3-Cyclobutylamino-6,7-dichloro-4H-1,2,4-benzothiadiazine 1,1-dioxide

6,7-Dichloro-3-(imidazol-1-yl)-4H-1,2,4-benzothiadiazine 1,1-dioxide monohydrate was treated with cyclobutylamine according to the general procedure Method D to give the title compound; m.p. 320-326°C; IR (KBr): 3290, 3163, 3068, 2979, 2952, 1631, 1580, 1556,
10 1460, 1331, 1251, 1166, 1152, 1137, 1128 cm^{-1} .

In the following, EXAMPLE 66 to 122, the 3-alkylamino-1,2,4-benzothiadiazine 1,1-dioxides were prepared from the appropriate 3-methylsulfanyl-1,2,4-benzothiadiazine 1,1-dioxides and the appropriate alkylamines according to the general procedure described
15 above. For each compound the applied method and data for the compound are given.

EXAMPLE 66

20 7-Chloro-3-(cyclohexylmethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method C; m.p. 277-279°C.

EXAMPLE 67

25

7-Chloro-3-(R)-(1-cyclohexylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method C; m.p. 177-182 °C; IR (KBr): 3300, 3187, 3085, 2927, 2853, 1631, 1581, 1483,
1251, 1162, 1105 cm^{-1} .

30

EXAMPLE 68

7-Chloro-3-(S)-(1-cyclohexylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method C; m.p. 177-182 °C; IR (KBr): 3300, 3185, 3084, 2927, 2853, 1632, 1578, 1483, 1243, 1162, 1105 cm⁻¹.

5

EXAMPLE 69

7-Chloro-3-(R)-(1-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

10 Method C; m.p. 178-181°C; IR (KBr): 3299, 3183, 3085, 2977, 1631, 1568, 1482, 1251, 1163, 1105 cm⁻¹.

EXAMPLE 70

15 7-Chloro-3-(S)-(1-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method C; m.p. 178-181°C; IR (KBr): 3299, 3186, 3086, 2977, 1631, 1568, 1482, 1251, 1163, 1105 cm⁻¹.

20

EXAMPLE 71

7-Chloro-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method D; m.p.: 275-278°C; IR (KBr): 3284, 3180, 3087, 2983, 1633, 1575, 1494, 1479, 25 1238, 1155, 1125, 1102 cm⁻¹; NMR (DMSO-d₆, HMDS; δ ppm): 1.20-2.30 (m, 6H, (CH₂)₃), 4.15 (m, 1H, NH-CH), 7.15 (d, 1H, 5-H), 7.50 (m, 2H, 6-H + NH-CH), 7.60 (s, 1H, 8-H), 10.25 (bs, 1H, NH).

EXAMPLE 72

30

7-Chloro-3-(2,2,2-trifluoroethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method A; m.p.: 302-304°C; IR (KBr): 3283, 3186, 3120, 3087, 1627, 1582, 1483, 1265, 1240, 1181, 1161, 1136, 1107 cm⁻¹.

EXAMPLE 73

5

3-Allylamino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method A; m.p.: 220-222°C; IR (KBr): 3310, 3185, 3089, 2988, 1651, 1630, 1584, 1483, 1239, 1164, 1138, 1105 cm⁻¹.

10

EXAMPLE 74

15

7-Chloro-3-(2-methoxy-1-methylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method B; m.p.: 150-153°C; IR (KBr): 3294, 3186, 3118, 3084, 2983, 2932, 2880, 1631, 1582, 1480, 1250, 1162, 1105 cm⁻¹.

EXAMPLE 75

20

7-Chloro-3-(1-ethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method B; m.p.: 233-236°C; IR (KBr): 3290, 3191, 3119, 3087, 2968, 2934, 2879, 2859, 1627, 1582, 1482, 1242, 1158, 1146, 1121, 1102 cm⁻¹; NMR (DMSO-d₆, HMDS; δ ppm):
25 0.75 (t, 6H, 2 x CH₃), 1.40 (quint., 4H, 2 x CH₂), 3.55 (m, 1H, NH-CH), 6.95 (b, 1H, NH-CH), 7.10 (d, 1H, 5-H), 7.50 (d, 1H, 6-H), 7.55 (s, 1H, 8-H), 10.30 (bs, 1H, NH).

EXAMPLE 76

30 7-Chloro-3-(2-hydroxypropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method B; m.p.: 248-250°C; IR (KBr): 3365, 3174, 3068, 2968, 1636, 1587, 1566, 1481,

1274, 1175, 1149 cm^{-1} .

EXAMPLE 77

5 7-Chloro-3-(2-hydroxy-1-methylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method B; m.p.: 216-217°C; IR (KBr): 3428, 3286, 3102, 1626, 1582, 1483, 1272, 1163, 1122, 1105 cm^{-1} ; NMR (DMSO- d_6 , HMDS; δ ppm): 1.05 (d, 3H, CH_3), 3.30 (bd, 2H, CH_2), 3.80 (m, 1H, NH-CH), 4.85 (b, 1H, OH), 6.90 (bd, 1H, NH-CH), 7.10 (d, 1H, 5-H), 7.50 (d, 1H, 6-H), 7.55 (s, 1H, 8-H), 10.50 (bs, 1H, NH).

10

EXAMPLE 78

7-Chloro-3-(2,2-diethoxyethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method B; m.p.: 219-220°C; IR (KBr): 3367, 3194, 3092, 2978, 1627, 1611, 1585, 1570, 15
1486, 1251, 1169, 1135, 1105 cm^{-1} ; NMR (DMSO- d_6 , HMDS; δ ppm): 1.05 (t, 6H, 2 x CH_3), 3.25 (bd, 2H, $\text{NH-CH}_2\text{-CH}$), 3.55 (q, 4H, 2 x CH_2), 4.55 (t, 1H, $\text{NH-CH}_2\text{-CH}$), 7.00 (b, 1H, $\text{NH-CH}_2\text{-CH}$), 7.10 (d, 1H, 5-H), 7.55 (d, 1H, 6-H), 7.60 (s, 1H, 8-H), 10.65 (b, 1H, NH).

20

EXAMPLE 79

7-Chloro-3-hexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method B; m.p.: 218-220°C.

25

EXAMPLE 80

3-(2-Butyl)amino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide

30

Method A; m.p.: 253-254°C; IR (KBr): 3318, 2969, 1618, 1573, 1476, 1274, 1247, 1149, 1114 cm^{-1} .

EXAMPLE 81

7-Iodo-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

5

Method B; m.p.: 267-270°C; IR (KBr): 3317, 2961, 1616, 1573, 1475, 1276, 1248, 1156, 1115 cm⁻¹.

EXAMPLE 82

10

7-Iodo-3-(1,2,2-trimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method B; m.p.: 309-310°C; IR (KBr): 3336, 2961, 1620, 1573, 1559, 1475, 1277, 1253, 1148, 1114 cm⁻¹.

15

EXAMPLE 83

3-(Cyclohexylmethyl)amino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide

20 Method C ; m.p.: 285-287°C; IR (KBr): 3312, 2922, 2850, 1614, 1574, 1563, 1474, 1280, 1254, 1148, 1117 cm⁻¹.

EXAMPLE 84

25 3-(R)-(1-Cyclohexylethyl)amino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method C ; m.p.: 281-284°C; IR (KBr): 3361, 3288, 3200, 2921, 2849, 1629, 1600, 1573, 1475, 1279, 1256, 1162, 1122 cm⁻¹.

30

EXAMPLE 85

3-(S)-(1-Cyclohexylethyl)amino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method C; m.p.: 288-290°C; IR (KBr): 3361, 3289, 3201, 2922, 2848, 1628, 1600, 1573, 1475, 1279, 1256, 1161, 1123 cm⁻¹.

5

EXAMPLE 863-Benzylamino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method C; m.p.: 254-257°C; IR (KBr): 3289, 3183, 3087, 1626, 1575, 1477, 1268, 1260,
10 1235, 1152, 1127 cm⁻¹.

EXAMPLE 877-Iodo-3-(R)-(1-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

15

Method C; m.p.: 234-236°C; IR (KBr): 3360, 3281, 3191, 3077, 1627, 1600, 1567, 1473, 1281, 1255, 1162, 1132 cm⁻¹.

EXAMPLE 88

20

7-Iodo-3-(S)-(1-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method C; m.p.: 236-239°C; IR (KBr): 3360, 3281, 3191, 3076, 1626, 1600, 1567, 1473, 1280, 1255, 1162, 1132 cm⁻¹.

25

EXAMPLE 893-(3-Pentyl)amino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide

30 Method B; m.p.: 210-220°C; IR (KBr): 3314, 2966, 2938, 2876, 1617, 1574, 1475, 1277, 1250, 1151, 1118 cm⁻¹; NMR (DMSO-d₆, HMDS; δ ppm): 0.80 (t, 6H, 2 x CH₃), 1.40 (quint., 4H, 2 x CH₂), 3.60 (m, 1H, NH-CH), 6.95 (bm, 2H, 5-H + NH-CH), 7.75 (d, 1H, 6-

H), 7.85 (s, 1H, 8-H). 10.25 (bs, 1H, NH).

EXAMPLE 90

5 7-Bromo-3-sec-butylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method A; m.p.: 224-226°C; IR (KBr): 3320, 3105, 2971, 2933, 2879, 1622, 1579, 1480, 1277, 1253, 1158, 1150, 1115 cm⁻¹.

10

EXAMPLE 91

7-Bromo-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method B; m.p.: 254-256°C; IR (KBr): 3319, 2963, 2876, 1618, 1578, 1562, 1478, 1282,
15 1252, 1160, 1151, 1116, 1101 cm⁻¹.

EXAMPLE 92

7-Bromo-3-cyclopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

20

Method A; m.p.: 248-253°C; IR (KBr): 3274, 3198, 3140, 1621, 1588, 1528, 1483, 1445, 1342, 1251, 1158, 1147, 1101 cm⁻¹.

EXAMPLE 93

25

7-Bromo-3-methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide monohydrate

Method A (using a 40% w/v solution of methylamine in water)

m.p.: 305-307°C

30

EXAMPLE 94

7-Bromo-3-ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method A (using a 70% w/v solution of ethylamine in water)

m.p.: 267-268°C

5 IR (KBr): 3305, 3189, 3123, 2972, 1630, 1583, 1478, 1249, 1159, 1122 cm⁻¹

EXAMPLE 957-Bromo-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

10

Method D

m.p.: 279-281°C

IR (KBr): 3288, 3175, 3081, 2984, 1631, 1580, 1563, 1480, 1258, 1242, 1153, 1123 cm⁻¹

15

EXAMPLE 967-Bromo-3-(2,2,2-trifluoroethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method A

20 m.p.: 298-301°C

EXAMPLE 977-Bromo-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

25

Method A

m.p.: 234-235°C

EXAMPLE 98

30

7-Fluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method A

m.p.: 242-244°C

IR (KBr): 3304, 3177, 3084, 2986, 1639, 1619, 1594, 1568, 1509, 1493, 1267, 1258, 1242, 1178, 1148, 1119, 1108 cm⁻¹

5 NMR (DMSO-d₆, HMDS; δ ppm): 1.10 (d, 6H, 2 x CH₃), 3.90 (m, 1H, NH-CH), 7.00 (bd, 1H, NH-CH), 7.10-7.50 (m, 3H, 5-H + 6-H + 8-H), 10.25 (bs, 1H, NH)

EXAMPLE 99

10 3-(2-Butyl)amino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide monohydrate

Method A

m.p.: 203-205°C

IR (KBr): 3545, 3492, 3348, 3080, 2974, 1651, 1636, 1618, 1595, 1568, 1498, 1267,
15 1180, 1159, 1115 cm⁻¹

EXAMPLE 100

20 7-Fluoro-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method B

m.p.: 193-198°C

IR (KBr): 3298, 3189, 3089, 2968, 1636, 1616, 1593, 1572, 1504, 1494, 1258, 1168,
25 1147, 1110 cm⁻¹

EXAMPLE 101

3-Ethylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide

30 Method A (using a 70% w/v aqueous solution of ethylamine)

m.p.: 235-237°C

IR (KBr): 3289, 3194, 3127, 3086, 2987, 2891, 1636, 1620, 1593, 1579, 1505, 1491,

1260, 1240, 1159, 1145, 1112 cm^{-1}

EXAMPLE 102

5 7-Fluoro-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method A

m.p.: 199-202°C

10

EXAMPLE 103

3-Cyclopropylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method A

15 m.p.: 242-245°C

EXAMPLE 104

3-Cyclobutylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide

20

Method D

m.p.: 252-253°C

IR (KBr): 3303, 3176, 3085, 2983, 1640, 1619, 1595, 1566, 1508, 1493, 1260, 1245,
1169, 1151, 1138, 1117 cm^{-1}

25

EXAMPLE 105

3-Cyclopentylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide

30 Method B

m.p.: 237-239°C

IR (KBr): 3299, 3176, 3084, 3008, 2982, 2874, 1640, 1619, 1593, 1569, 1509, 1493,

1266, 1258, 1241, 1160, 1137, 1112 cm^{-1}

EXAMPLE 106

5 3-(Cyclopropylmethyl)amino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method D

m.p.: 221-222°C

IR (KBr): 3295, 3187, 3086, 3008, 2884, 1641, 1620, 1592, 1508, 1496, 1270, 1256,
10 1240, 1155, 1137, 1115 cm^{-1}

EXAMPLE 107

3-Allylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide

15

Method A

m.p.: 209-210°C

IR (KBr): 3353, 3312, 3187, 3087, 2989, (1636), 1615, 1595, 1569, 1493, 1259, 1164,
1141, 1119 cm^{-1}

20

EXAMPLE 108

7-Fluoro-3-(3-methoxy-2-propyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide (or 7-Fluoro-3-(2-methoxy-1-methylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide)

25

Method B

m.p.: 148-149°C

IR (KBr): 3309, 3201, 3137, 3099, 2986, 2934, 2900, 1636, 1618, 1594, 1580, 1507,
1494, 1260, 1149, 1111 cm^{-1}

30

EXAMPLE 109

7-Fluoro-3-methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide monohydrate

Method A (using a 40% w/v aqueous solution of methylamine)

m.p.: 275-277°C

EXAMPLE 110

5

3-(2,2-Diethoxyethyl)amino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method B

m.p.: 202-203°C

10

EXAMPLE 111

7-Fluoro-3-(2,2,2-trifluoroethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method A

15 m.p.: 269-271°C

EXAMPLE 112

3-Cyclobutylamino-7-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

20

Method D

m.p.: 289-290°C

IR (KBr): 3285, 3179, 3088, 2986, 2947, 1631, 1587, 1568, 1500, 1269, 1239, 1149, 1122
cm⁻¹

25

EXAMPLE 113

3-Isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method A

30 m.p.: 227-233°C

IR (KBr): 3285, 3128, 2969, 2925, 1628, 1609, 1580, 1505, 1273, 1254, 1147, 1121, 1109
cm⁻¹

NMR (DMSO-d₆, HMDS; δ ppm): 1.10 (d, 6H, 2 x CH₃), 3.70 (s, 3H, OCH₃), 3.90 (m, 1H, NH-CH), 6.85 (bd, 1H, NH-CH), 7.10 (s, 3H, 5-H + 6-H + 8-H), 10.05 (bs, 1H, NH)

EXAMPLE 114

5

7-Methoxy-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide monohydrate

Method A

m.p.: 194-199°C

10

EXAMPLE 115

6-Chloro-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

15 Method D

m.p. 306-307°C

IR (KBr): 3333, 3285, 3181, 3079, 2993, 2951, 1631, 1583, 1549, 1470, 1245, 1167, 1149, 1124 cm⁻¹

20

EXAMPLE 116

6-Chloro-3-(2,2,2-trifluoroethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method A

25 m.p.: 320-323°C

IR (KBr): 3298, 3185, 3122, 3082, 3023, 2977, 1636, 1586, 1574, 1473, 1257, 1245, 1188, 1167, 1152, 1134 cm⁻¹

EXAMPLE 117

30

6-Chloro-3-cyclopropylmethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method D

m.p. 278-280°C

IR (KBr): 3304, 3173, 3071, 3009, 2979, 1636, 1584, 1560, 1473, 1242, 1164, 1124 cm⁻¹

5

EXAMPLE 118

5-Chloro-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method D

10 m.p. 222-224°C

EXAMPLE 119

5-Chloro-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

15

Method A

m.p.: 196-197°C

EXAMPLE 120

20

5-Chloro-3-hexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method B

m.p.: 164-165°C

25

EXAMPLE 121

6-Chloro-3-octylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

30 Method C

m.p.: 231-232°C

EXAMPLE 122

6-Chloro-3-(1,5-dimethylhexyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

Method C

m.p.: 207-208°C

5

EXAMPLE 1237-Chloro-4-methyl-3-methylsulfanyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 10 A solution of 7-chloro-3-methylsulfanyl-4H-1,2,4-benzothiadiazine 1,1-dioxide (0.8 g) in acetonitrile (24 mL) and methanol (0.5 mL) was supplemented with potassium carbonate (0.96 g), then with methyl iodide (3 mL), and stirred at room temperature for 10 h. The solvent was removed by distillation under reduced pressure. The residue was suspended in water (40 mL) and the pH was adjusted to pH 2 with formic acid. The precipitate of the
- 15 title compound was collected by filtration, washed with water and dried. The compound was used without further purification in the next step (yield: 0.53 g).

7-Chloro-3-isopropylamino-4-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide hemi-hydrate

- 20 A mixture of 7-chloro-4-methyl-3-methylsulfanyl-4H-1,2,4-benzothiadiazine 1,1-dioxide (0.4 g) in isopropylamine (4 mL) was refluxed for 90 min. The amine was removed by distillation under reduced pressure, and the residue was suspended in water (20 mL). After stirring for 1 h at room temperature, the precipitate of the crude title compound was collected by filtration, washed with water and recrystallized from methanol:water (yield:
- 25 0.27 g); m.p. 176-183 °C;

EXAMPLE 1243-(2-Aminoethyl)amino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide monohydrate

30

A solution of 7-chloro-3-methylsulfanyl-4H-1,2,4-benzothiadiazine 1,1-dioxide (1 g) in ethylenediamine (2.5 mL) was refluxed for 45 min. Most of the excess of amine was

removed by distillation under reduced pressure and the resulting oily residue was dissolved in methanol (10 mL). Addition of diethylether (40 mL) gave rise to the precipitation of an oil which turned to a white solid after a stirring of 30 min. at 0°C. The precipitate was collected by filtration, washed with diethylether and dried. The solid was dissolved in 5 boiling water (40 mL) and traces of insoluble material were removed by filtration. The filtrate was concentrated to the half volume by distillation under reduced pressure and placed at +4°C for 2 h. The crystalline precipitate of the title compound was collected by filtration, washed with a small volume of water and dried to give the title compound (yield: 0.62 g); m.p. 200-204°C; IR (KBr): 3498, 3372, 2932, 1637, 1560, 1481, 1264, 1163 cm⁻¹;
10 ¹H-NMR (DMSO-d₆, HMDS; δ ppm): 2.70 (t, 2H, NH-CH₂-CH₂-NH₂), 3.20 (t, 2H, NH-CH₂-CH₂-NH₂), 5.25 (b, 6H, 2 x NH + H₂O + NH₂), 6.95 (d, 1H, 5-H), 7.30 (d, 1H, 6-H), 7.45 (s, 1H, 8-H).

EXAMPLE 125

15

3-Isopropylamino-4H-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide

a) 3-Oxo-2,3-dihydro-4H-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide monohydrate

20

7-Methyl-3-oxo-2,3-dihydro-4H-1,2,4-benzothiadiazine 1,1-dioxide (20 g) was suspended in hot water (2000 mL) and supplemented dropwise with a 10 % aqueous solution of NaOH until complete dissolution. Potassium permanganate (60 g) was added portionwise and the reaction mixture was stirred for 3 h at 70°C. After cooling, the insoluble material
25 was removed by filtration and the purple filtrate was treated with sodium hydrogen sulfite until complete discolouration of the excess of permanganate. The solution was treated with charcoal, filtered, and the filtrate was adjusted to pH 0 with 12N HCl. The resulting suspension was placed at +4°C during 2 h and the crystalline precipitate was collected by filtration, washed with water and dried (yield: 14.5 g); m.p.: 305-308°C

30

b) 4-Amino-3-sulfamoylbenzoic acid

A suspension of 3-oxo-2,3-dihydro-4*H*-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide monohydrate (10 g) in a mixture of concentrated sulfuric acid (150 mL) and water (150 mL) was refluxed until complete dissolution of the starting material (1-2 h). The resulting solution was placed on an ice bath and supplemented dropwise with a 20% aqueous solution of NaOH under stirring and cooling until pH 1-2. The precipitate was collected by filtration, washed with water and dried (yield: 6.6 g); m.p.: 214-219 °C.

c) 3-(Imidazol-1-yl)-4*H*-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide

4-Amino-3-sulfamoylbenzoic acid (6 g) and thiocarbonyldiimidazole (23.2g) in dioxane (60 mL) was refluxed for 2 h. The solvent was removed by distillation under reduced pressure. The residue was dispersed in water (200 mL) and supplemented with a 10% aqueous solution of NaOH (40 mL). After stirring for 30 min. at room temperature, the solution was treated with charcoal, filtered, and the filtrate was adjusted to pH 2 with 12N HCl. The resulting precipitate was collected by filtration, washed with water and dried to give the title compound (yield: 4.5 g); m.p. >300°C.

d) 3-Isopropylamino-4*H*-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide

3-(Imidazol-1-yl)-4*H*-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide was treated with isopropylamine according to the general procedure Method A to give the title compound; m.p. >310 °C.

EXAMPLE 126

3-sec-Butylamino-4*H*-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide

3-(Imidazol-1-yl)-4*H*-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide was treated with sec-butylamine according to the general procedure Method A to give the title compound; m.p. >310 °C.

EXAMPLE 127

3-Propylamino-4H-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide

3-(Imidazol-1-yl)-4H-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide was treated with
5 propylamine according to the general procedure Method A to give the title compound; m.p.
>310°C

EXAMPLE 128

10

3-Isopropylamino-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

a) 2-Amino-5-trifluoromethylbenzenesulfonamide

15 A solution of 2-benzylamino-5-trifluoromethylbenzenesulfonamide (7.3 g) in methanol (80 mL) was supplemented with 10% Pd/C (0.73 g) and submitted to hydrogen under pressure (4 bars) during 90 min. at room temperature. The insoluble material was removed by filtration and the filtrate was concentrated to dryness. The residue was crystallized in methanol-water to give the title compound (yield: 5 g); m.p. 142-143°C.

20

b) 3-(Imidazol-1-yl)-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

The procedure described for 3-(imidazol-1-yl)-4H-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide was used for the preparation of the title compound starting from 2-amino-5-
25 trifluoromethylbenzenesulfonamide (4.5 g) and using a refluxing time of 4 h. The crude compound was recrystallized from methanol-diethylether (yield: 1.9 g); m.p. 211-214°C.

c) 3-Isopropylamino-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

30 3-(Imidazol-1-yl)-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide was treated with isopropylamine according to the general procedure Method A to give the title compound; m.p. 287-289 °C.

EXAMPLE 1293-sec-Butylamino-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

5

3-(Imidazol-1-yl)-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide was treated with sec-butylamine according to the general procedure Method A to give the title compound; m.p. 234-236 °C.

10

EXAMPLE 1303-Propylamino-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

3-(Imidazol-1-yl)-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide was treated with
15 propylamine according to the general procedure Method A to give the title compound; m.p. 241-243 °C.

EXAMPLE 131

20 3-Cyclopropylmethylamino-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

3-(Imidazol-1-yl)-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide was treated with cyclopropylmethylamine according to the general procedure Method D to give the title compound; m.p. 266-268 °C.

25

EXAMPLE 1327-Fluoro-3,6-di(isopropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide

30 a) 2-Amino-4,5-difluorobenzenesulfonamide

3,4-Difluoroaniline (20 g) in chlorosulfonic acid (60 mL) was heated for 1 h at 140°C. After cooling at 70°C, the reaction mixture was supplemented with thionyl chloride (30 mL) and

refluxed for 2 h. After cooling, the mixture was poured on ice water (200 g) and extracted three times with diethyl ether (3 x 100 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated to dryness under reduced pressure. The oily residue was dissolved in dioxane (100 mL) and added under stirring to a 10% w/v aqueous solution of ammonia (300 mL). After 1 h, the resulting solution was treated with charcoal, filtered and concentrated to a volume of 100 mL, then adjusted to pH 3. After standing overnight at +4°C, the precipitate was collected by filtration and washed with the minimum of water (first part). The filtrate was extracted three times with ethyl acetate (3 x 100 mL). The combined organic layers were dried over MgSO₄, filtered, and the filtrate was concentrated to dryness. The residue was suspended in a small volume of water, and the insoluble material was collected by filtration, washed with a minimum of water and dried (second part) (total yield of crude compound : 5.5 g); m.p. 137-142°C (methanol-diethylether).

15 b) 6,7-Difluoro-3-(imidazol-1-yl)-4H-1,2,4-benzothiadiazine 1,1-dioxide

The procedure described for 3-(imidazol-1-yl)-4H-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide was used for the preparation of the title compound starting from 2-amino-4,5-difluorobenzenesulfonamide (5 g) and using a refluxing time of 4 h. The crude compound was recrystallized from acetone-diethylether (yield : 2.6 g); m.p. 264-266°C.

c) 7-Fluoro-3,6-di(isopropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide

6,7-Difluoro-3-(imidazol-1-yl)-4H-1,2,4-benzothiadiazine 1,1-dioxide was treated with isopropylamine according to the general procedure Method A to give the title compound; m.p. 234-237°C.

EXAMPLE 133

30 3-Ethylamino-6,7-difluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide

Starting from 2-amino-4,5-difluorobenzenesulfonamide and ethyl isothiocyanate, and

following a procedure analogous to the one described in Example 4a, N-(2-amino-4,5-difluorobenzenesulfonyl)-N'-ethylthiourea was prepared. The crude compound was used without further purification in a cyclisation step analogous to the one described in Example 4b to give the title compound; m.p. 246-252 °C.

5

EXAMPLE 134

7-Chloro-3-(pyridin-2-yl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

10-a) 7-Chloro-3-methylsulfinyl-4H-1,2,4-benzothiadiazine 1,1-dioxide

A suspension of 7-chloro-3-methylsulfinyl-4H-1,2,4-benzothiadiazine 1,1-dioxide (0.5 g) in an aqueous solution of sodium hydrogen carbonate (0.22 g/25 mL) was supplemented dropwise with 2M NaOH until complete dissolution. Liquid bromine (0.1 mL) was added under stirring at room temperature. After 10 min., the resulting suspension was adjusted to pH 2-3 with 6N HCl and the insoluble material was collected by filtration and washed with water. The white precipitate was suspended in methanol (20 mL), stirred for 1 h and then collected by filtration, washed with methanol and dried (yield : 0.45 g); m.p. 260-261 °C.

20

b) 7-Chloro-3-(pyrid-2-yl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

7-Chloro-3-methylsulfinyl-4H-1,2,4-benzothiadiazine 1,1-dioxide (0.25 g) and 2-aminopyridine (0.25 g) in 3-chlorotoluene (5 mL) was heated at 150°C for 1 h. After cooling, the white precipitate was collected by filtration and washed with diethylether. The insoluble material was dissolved in 1M NaOH (20 mL), treated with charcoal, filtered, and the filtrate was adjusted to pH 3 with 6N HCl. The precipitate was collected by filtration, washed with water, dissolved in hot DMF (15 mL), mixed with an equal volume of distilled water and cooled. The white precipitate was collected by filtration, washed with water and dried (yield : 0.12 g); m.p. >310°C.

30

EXAMPLE 135

7-Chloro-3-(2-formylaminoethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

A mixture of formic acid (1 mL) and acetic anhydride (2 mL) was heated at 50°C for 20 min. After cooling at room temperature, 3-(2-aminoethyl)amino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide monohydrate (0.5 g) was added, and the reaction mixture was stirred for 2 h, then supplemented with water (20 mL) and stirred for 20 min. The precipitate was collected by filtration, washed with water and dried (yield : 0.3 g); m.p. 245-247 °C.

10

EXAMPLE 136

3-(2-Acetylaminoethyl)amino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide

The same process as described in the preceding example was used for the synthesis of the title compound using 3-(2-aminoethyl)amino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide monohydrate (0.5 g) and acetic anhydride (3 mL) instead of the mixture of formic acid and acetic anhydride (yield : 0.25 g); m.p. 295-297 °C.

EXAMPLE 137

20

7-Chloro-3-(1,2-dimethylpropyl)amino-2-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide

To 10 ml of dry tetrahydrofuran stirred under nitrogen was added successively titanium tetrachloride (0.2 ml), anisole (0.5 ml), 1,2-dimethylpropylamine (0.8 ml), and then a slurry of 7-chloro-2,3-dihydro-2-methyl-3-oxo-4H-1,2,4-benzothiadiazine 1,1-dioxide (400 mg) in a mixture of 1,2-dimethylpropylamine (0.4 ml) and 5 ml of dry toluene. The mixture was heated at 120 °C. After 1½ h an additional amount of 1,2-dimethylpropylamine (0.4 ml) was added. After 2½ h the reaction mixture was cooled to room temperature. Isopropyl alcohol (1 ml), concentrated ammonium hydroxide (1 ml) and diatomaceous earth (0.5 g) was added and stirring was continued for 15 min. The insoluble material was removed by filtration and the filter cake rinsed with two portions of 25 ml of ethyl acetate. The organic phases were combined and shaken with 25 ml of water, then with 25 ml of saturated

30

aqueous sodium chloride, dried over sodium sulfate and the solvent was removed in vacuo. The residue was dissolved in 50 ml of ethyl acetate and extracted with 2x 50 ml of 4 M hydrochloric acid. The aqueous extracts were made alkaline with concentrated ammonium hydroxide and then extracted with 2 x 50 ml of ethyl acetate. The organic phase was dried over sodium sulfate and the solvent removed in vacuo. The residue was purified on a silica gel column with a 7:3 mixture of n-heptane and ethyl acetate as solvent to give the title compound as white crystals; m.p. 102-105 °C.

EXAMPLE 138

10

7-Chloro-3-isopropylamino-2-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide

Triethyloxonium tetrafluoroborate (0.95 g) in 10 ml of dry dichloromethane was added under nitrogen to a stirred suspension of 7-chloro-2,3-dihydro-2-methyl-3-oxo-4H-1,2,4-benzothiadiazine 1,1-dioxide (0.5 g) in 25 ml of dichloromethane at room temperature, and stirred overnight. Then the mixture was poured into 50 ml of a stirred saturated aqueous sodium bicarbonate solution. The organic layer was dried over sodium sulfate and the solvent was removed in vacuo. The residue consisting of 0.47 g of crude 7-chloro-3-ethoxy-2-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide was processed further without purification.

A mixture of crude 7-chloro-3-ethoxy-2-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide (0.45 g) and isopropylamine (4 ml) in an ethanolic sodium ethoxide solution, prepared by dissolving 0.4 g of sodium in 10 ml of ethanol, was refluxed for 3 hours and then neutralized with 4M acetic acid. The mixture was evaporated to dryness and partitioned between 25 ml of water and 25 ml of dichloromethane. The organic layer was dried over sodium sulfate and the solvent was evaporated in vacuo. The residue was purified by chromatography on a silica gel column with a 7:3 mixture of n-heptane and ethyl acetate as solvent to give the title compound;

¹H-NMR (CDCl₃), δ (ppm): 7.7 (d, 1H), 7.47 (dd, 1H), 7.25 (d, 1H), 4.45 (br, 1H, NH), 4.38-4.18 (m, 1H, CH), 3.31 (s, 3H, CH₃), 1.29 (d, 6H, CH₃); m.p. 139-141°C..

EXAMPLE 1397-Chloro-3-(N-ethyl-N-methylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide

5

Starting from 3,7-dichloro-4H-1,2,4-benzothiadiazine 1,1-dioxide (753 mg; 3 mmol) and N-ethyl-N-methylamine (708 mg; 12 mmol) and with the use of same procedure as in example 21 650 mg (79 %) of the title compound was prepared; m.p. >220 °C; ¹H-NMR (DMSO-d₆) ppm; 10.4 (s, 1H, NH), 7.69 (d, 1H, H-8), 7.61 (dd, 1H, H-6), 7.55 (d, 1H, H-5), 3.5 (q, 2H, CH₂), 3.09 (s, 3H, CH₃), 1.10 (t, 3H, CH₃); ¹³C-NMR (DMSO-d₆) ppm; 150.21, 134.69, 131.81, 127.27, 123.98, 121.42, 119.54, 44.2, 34.69, 11.91. Analysis C₁₀H₁₂ClN₃O₂S requires C 43.88 , H 4.42 , N 15.35 (found C 43.52 , H 4.55 , N 15.30).

10

EXAMPLE 140

15

6-Chloro-3-(N-ethyl-N-methylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide

Starting from 3,6-dichloro-4H-1,2,4-benzothiadiazine 1,1-dioxide (500 mg; 1.99 mmol) and N-ethyl-N-methylamine (500 mg; 8.47 mmol) and with the use of same procedure as in example 21 200mg (36.7 %) of the title compound was prepared; m.p. >220 °C; ¹H-NMR (DMSO-d₆) ppm; 10.35 (s, 1H, NH), 7.65 (d, 1H, H-8), 7.58 (dd, 1H, H-5), 7.3 (d, 1H, H-7), 3.5 (q, 2H, CH₂), 3.11 (s, 3H, CH₃), 1.14 (t, 3H, CH₃). Analysis: C₁₀H₁₂ClN₃O₂S requires C 43.88 , H 4.42 , N 15.35 (found C 43.78 , H 4.51 , N 15.24).

20

25

EXAMPLE 1417-Chloro-3-(3-(1H-imidazol-4-yl)propyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

A suspension of 3,7-dichloro-4H-1,2,4-benzothiadiazine 1,1-dioxide (200 mg; 0.8 mmol) and 3-(1-trityl-1H-imidazo-4(5)-yl)-propylamine (339 mg; 1.2 mmol) in ethanol (3 ml) was stirred at 90 °C in a sealed flask for 16 h. The reaction mixture was concentrated *in vacu.* To the residue was added 6N HCl and extracted with dichloromethane. The aqueous phase was brought to pH 10 with 10N NaOH and extracted with dichloromethane. The

30

aqueous phase was concentrated. The residue was purified by flash chromatography using ethanol / 25% aqueous ammoniumhydroxide 10:1 as eluent to give the title compound (133 mg, 49%)

¹H-NMR (DMSO-d₆), δ(ppm): 7.6 (m, 3H), 7.25 (br, 1H, NH), 6.80 (s, 1H), 3.4 (br, NH + HDO), 3.25 (q, 2H, CH₂), 2.48 (m, 2H + DMSO, CH₂), 1.78 (m, 2H, CH₂); MS:EI/70eV: 339, 341 (³⁵Cl, ³⁷Cl) [M+].

EXAMPLE 142

10 3-(1-Benzylpyrrolidin-3-ylamino)-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide

A suspension of 3,7-dichloro-4H-1,2,4-benzothiadiazine 1,1-dioxide (100 mg; 0.4 mmol) 1-benzyl-3-aminopyrrolidine (0.35 ml; 2.0 mmol) was stirred at 110 °C for 72 h. The reaction mixture was concentrated *in vacuo* and the residue was purified by flash chromatography using ethyl acetate / methanol 10:1 to give oily crystals (114 mg). These were recrystallised from ethyl acetate to give the title compound as white crystals (83 mg, 53%); m.p. 208.5-209.5 °C;


¹H-NMR (DMSO-d₆), δ(ppm): 10.6 (br, 1H, NH), 7.65 (d, 1H), 7.50 (dd, 1H), 7.4 (br, 1H, NH), 7.3 (m, 5H, Ph), 7.20 (d, 1H), 4.25 (m, 1H), 3.60 (s, 2H, CH₂Ph), 2.7 (m, 2H), 2.5 (m, 20 1H + DMSO), 2.32 (m, 1H), 2.22 (m, 1H), 1.68 (m, 1H); MS:EI/70eV: 389 [M-1].

Analysis: calc. For C ₁₈ H ₁₉ ClN ₄ O ₂ S x 0.25 H ₂ O	C 54.68	H 4.97	N 14.17
found	C 54.79	H 4.96	N 13.95

CLAIMS

1. A compound of the general formula I:

5



(I)

10 wherein

R¹ and R⁵ independently can be hydrogen; hydroxy; C₁₋₆-alkoxy; C₃₋₆-cycloalkyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen and R⁴ is hydrogen; or

15

R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3 of formula I and R¹ is as defined above; or

R⁴ together with R¹ represent one of the bonds in a double bond between the atoms 3 and
20 4 of formula I and R⁵ is as defined above;

D represents -S(=O)₂- or -S(=O)-;

R² is hydrogen; hydroxy; C₁₋₆-alkoxy; C₃₋₆-cycloalkyl optionally mono- or polysubstituted
25 with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen;

R^3 is R^8 ; $-OR^8$; $-C(=X^1)R^8$; bicycloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl optionally mono- or polysubstituted with halogen, hydroxy, C_{1-6} -alkyl, C_{1-6} -alkoxy, aryloxy, arylalkoxy, nitro, amino, C_{1-6} -monoalkyl- or dialkylamino, cyano, oxo, acyl or C_{1-6} -alkoxycarbonyl;

5


wherein R^8 is hydrogen; C_{3-6} -cycloalkyl or $(C_{3-6}$ -cycloalkyl) C_{1-6} -alkyl the C_{3-6} -cycloalkyl group optionally being mono- or polysubstituted with C_{1-6} -alkyl, halogen, hydroxy or C_{1-6} -alkoxy; a 3-6 membered saturated ring system comprising one or more nitrogen-, oxygen- or sulfur atoms, optionally being mono- or polysubstituted with halogen, cyano,

10 trifluoromethyl, C_{1-6} -alkyl, C_{1-6} -alkoxy, C_{1-6} -alkoxy- C_{1-6} -alkyl, aryl, arylalkyl, hydroxy, oxo, nitro, amino, C_{1-6} -monoalkyl or dialkylamino; or straight or branched C_{1-18} -alkyl optionally mono- or polysubstituted with halogen, hydroxy, C_{1-6} -alkoxy, C_{1-6} -alkylthio, C_{3-6} -cycloalkyl, aryl, aryloxy, arylalkoxy, nitro, amino, C_{1-6} -monoalkyl- or dialkylamino, cyano, oxo, formyl, acyl, carboxy, C_{1-6} -alkoxycarbonyl, carbamoyl, formylamino, or C_{1-6} -alkylcarbonylamino;

15

X^1 is O or S;

R^3 is



20

wherein n, m, p independently can be 0, 1, 2, 3 and R^{10} is hydrogen; hydroxy; C_{1-6} -alkoxy; C_{3-6} -cycloalkyl optionally mono- or polysubstituted with C_{1-6} -alkyl, halogen, hydroxy or C_{1-6} -alkoxy; or C_{1-6} -alkyl, C_{2-6} -alkenyl or C_{2-6} -alkynyl optionally mono- or polysubstituted with halogen;

25 R^{12} , R^{13} , R^{14} , R^{15} independently are hydrogen; halogen; C_{1-18} -alkyl; C_{3-6} -cycloalkyl; hydroxy;

C₁₋₆-alkoxy; C₁₋₆-alkoxy-C₁₋₆-alkyl; nitro; amino; cyano; cyanomethyl; perhalomethyl; C₁₋₆-monoalkyl- or dialkylamino; sulfamoyl; C₁₋₆-alkylthio; C₁₋₆-alkylsulfonyl; C₁₋₆-alkylsulfinyl; C₁₋₆-alkylcarbonylamino; formyl; arylthio, arylsulfinyl, arylsulfonyl, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; C₁₋₆-alkoxycarbonyl; C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl; carbamyl; carbamylmethyl; C₁₋₆-monoalkyl- or dialkylaminocarbonyl; C₁₋₆-monoalkyl - or dialkylaminothiocarbonyl; ureido; C₁₋₆-monoalkyl- or dialkylaminocarbonylamino, thioureido; C₁₋₆-monoalkyl- or dialkylaminothiocarbonylamino; C₁₋₆-monoalkyl- or dialkylaminosulfonyl; carboxy; carboxy-C₁₋₆-alkyl; acyl; aryl, arylalkyl, aryloxy, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl)-C₁₋₆-alkyl the oxadiazolyl group optionally being substituted with C₁₋₆-alkyl or C₃₋₆-cycloalkyl; or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl; or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form.

15

2. A compound according to the preceding claim wherein one of R¹ and R⁵ is hydrogen; hydroxy; C₁₋₆-alkoxy; C₃₋₆-cycloalkyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen; and the other of R¹ and R⁵ together with R⁴ is a bond.

20

3. A compound according to any of the preceding claims wherein D represents - S(=O)₂ - .

4. A compound according to any of the preceding claims wherein R² is hydrogen or C₁₋₆-alkyl.

25

5. A compound according to any of the preceding claims wherein R² is hydrogen.

6. A compound according to any of the preceding claims wherein R³ is R^a; OR^a; - C(=O)R^a; wherein R^a is hydrogen; C₃₋₆-cycloalkyl or (C₃₋₆-cycloalkyl)- C₁₋₆-alkyl, the C₃₋₆-cycloalkyl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy

30

or C₁₋₆-alkoxy; a 3-6 membered saturated ring system comprising one or more nitrogen-, oxygen- or sulfur atoms; or straight or branched C₁₋₁₈-alkyl optionally mono- or polysubstituted with halogen, C₃₋₆-cycloalkyl, hydroxy or C₁₋₆-alkoxy.

5 7. A compound according to any of the preceding claims wherein R³ is secondary C₃₋₆-alkyl, tertiary C₄₋₆-alkyl, C₃₋₆-cycloalkyl or (C₃₋₆-cycloalkyl)methyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy.

8. A compound according to any of the preceding claims wherein R¹², R¹³, R¹⁴, R¹⁵
10 independently are halogen.

9. A compound according to any of the preceding claims wherein R¹³ is halogen.

10. A compound according to claim 1 selected from

- 15 7-Chloro-3-(2-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Bromo-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6,8-Dichloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-Isopropylamino-6-methanesulfonyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-Isopropylamino-6-benzenesulfonyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 20 5-Chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-Isopropylamino-6-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Chloro-3-isopropylamino-7-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Ethoxycarbonylmethyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 8-Chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 25 6-Isopropyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-tert-Butyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-Isopropylamino-6-phenoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Hexyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Cyclohexyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 30 6-Chloro-3-(1-ethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Carboxymethyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)methyl-3-isopropylamino-4H-1,2,4-benzothiadiazine

- 1,1-dioxide
- 2-(3-Isopropylamino-1,1-dioxo-1,4-dihydro-1 λ 6,2,4-benzothiadiazin-6-yl)-acetamide
- 6-Cyanomethyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-Benzyloxyamino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 5 7-Chloro-3-methoxyamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Chloro-3-butylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Chloro-3-hexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Bromo-6-trifluoromethyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6,7-Dichloro-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 10 6-Chloro-3-(1,2,2-trimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Bromo-3-(1,2,2-trimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6,7-Dichloro-3-(1-methylbutyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 5-Amino-7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Chloro-3-(1,3-dimethylpentyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 15 7-Chloro-3-(1,5-dimethylhexyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Chloro-3-(1,4-dimethylpentyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 5,7-Dichloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Chloro-3-(3,3-diphenylpropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Chloro-3-(4-phenylbutylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 20 6-Chloro-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Chloro-3-(1,2-dimethylpropyl)amino-7-sulfamoyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-Anilino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Chloro-3-(4-pyridyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Chloro-3-isobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 25 3-sec-Butylamino-6-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Chloro-3-cyclohexylmethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Fluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-Cyclopentylamino-6-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Chloro-3-isopropylamino-5-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 30 3-tert-Butylamino-6-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-Iodo-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Chloro-7-fluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 3-Isopropylamino-6-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-cyclopropylmethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-7-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
5,7-Dibromo-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
5 6-Acetyl-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Allylamino-6-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-sec-Butylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-(1,2-Dimethylpropyl)amino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
10 3-Cyclopropylmethylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Nitro-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclobutylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Amino-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Acetamido-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
15 6,7-Dichloro-3-hexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6,7-Dichloro-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-cyclohexylmethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
(R)-7-Chloro-3-(1-cyclohexylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
(S)-7-Chloro-3-(1-cyclohexylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
20 (R)-7-Chloro-3-(1-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
(S)-7-Chloro-3-(1-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(2,2,2-trifluoroethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Allylamino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
25 7-Chloro-3-(2-methoxy-1-methylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(1-ethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(2-hydroxypropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(2-hydroxy-1-methylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(2,2-diethoxyethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
30 7-Chloro-3-hexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-sec-Butylamino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Iodo-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 7-Iodo-3-(1,2,2-trimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclohexylmethylamino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide
(R)-3-(1-Cyclohexylethyl)amino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide
(S)-3-(1-Cyclohexylethyl)amino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide
5 3-Benzylamino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide
(R)-7-Iodo-3-(1-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
(S)-7-Iodo-3-(1-phenylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-(1-Ethylpropyl)amino-7-iodo-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-sec-Butylamino-7-bromo-4H-1,2,4-benzothiadiazine 1,1-dioxide
10 7-Bromo-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Bromo-3-cyclopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Bromo-3-methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Bromo-3-ethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Bromo-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
15 7-Bromo-3-(2,2,2-trifluoroethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Bromo-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-sec-Butylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-(1,2-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
20 3-Ethylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclopropylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclobutylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclopentylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
25 3-Cyclopropylmethylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Allylamino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-(2-methoxy-1-methylethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3-methylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-(2,2-Diethoxyethyl)amino-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
30 7-Fluoro-3-(2,2,2-trifluoroethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclobutylamino-7-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide

- 7-Methoxy-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-(2,2,2-trifluoroethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-cyclopropylmethylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
5 5-Chloro-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
5-Chloro-3-propylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
5-Chloro-3-hexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-octylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-(1,5-dimethylhexyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
10 7-Chloro-3-isopropylamino-4-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-(2-Aminoethyl)amino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Isopropylamino-4H-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide
3-sec-Butylamino-4H-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide
3-Propylamino-4H-1,2,4-benzothiadiazine-7-carboxylic acid 1,1-dioxide
15 3-Isopropylamino-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-sec-Butylamino-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Propylamino-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-Cyclopropylmethylamino-7-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Fluoro-3,6-di(isopropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
20 3-Ethylamino-6,7-difluoro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(pyridin-2-yl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(2-formylaminoethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-(2-Acetylaminoethyl)amino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(1,2-dimethylpropyl)amino-2-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
25 7-Chloro-3-isopropylamino-2-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(N-ethyl-N-methylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-(N-ethyl-N-methylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
7-Chloro-3-(3-(1H-imidazol-4-yl)propyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
3-(1-Benzylpyrrolidin-3-ylamino)-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxide
30 or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form.

11. Compounds according to any one of the preceding claims which acts as openers of the K_{ATP} -regulated potassium channels.

12. A pharmaceutical composition comprising a compound according to any one of the
5 preceding claims or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form together with one or more pharmaceutically acceptable carriers or diluents.

10 13. A pharmaceutical composition for use in the treatment of diseases of the endocrinological system such as hyperinsulinaemia and diabetes comprising a compound according to any one of the preceding compound claims or a pharmaceutical acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form together
15 with a pharmaceutically acceptable carrier or diluent.

14. The pharmaceutical composition according to any one of the claims 12 or 13 in the form of an oral dosage unit or parenteral dosage unit.

20 15. A pharmaceutical composition according to any one of the claims 12 or 13 wherein said compound is administered as a dose in a range from about 0.05 to 1000, preferably from about 0.1 to 500 and especially in the range from 50 to 200 mg per day.

16. A compound according to any one of the preceding compound claims or a
25 pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for therapeutical use.

17. A compound according to any one of the preceding compound claims or a
30 pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for therapeutical use in the treatment of diseases of the endocrinological

system, such as hyperinsulinaemia and diabetes.

18. The use of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or
5 base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form as a medicament.

19. The use of a compound according to any of the preceding compound claims for
10 preparing a medicament.

20. The use of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or
base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or
any tautomeric form for the preparation of a medicament for the treatment of diseases of
15 the endocrinological system, such as hyperinsulinaemia and diabetes.


21. A method of treating diseases of the endocrinological system, such as hyperinsu-
linaemia and diabetes in a subject in need thereof comprising administering an effective
amount of a compound according to any one of the preceding compound claims to said
20 subject.

22. A process for the manufacture of a medicament, particular to be used in the
treatment of diseases of the endocrinological system, such as hyperinsulinaemia and
diabetes which process comprising bringing a compound of formula I according to any one
25 of the preceding compound claims 1 or a pharmaceutically acceptable salt thereof into a
galenic dosage form.

23. A method of preparing a compound of formula I which comprises:


30 a) reacting a compound of formula II:

97



(II)

5 wherein D, R¹, R⁴, R⁵, R¹², R¹³, R¹⁴ and R¹⁵ are as defined in claim 1 and Z is a leaving group with a compound of formula III:




(III)

10

wherein R² and R³ are as defined in claim 1 to form a compound of the general formula I,
or;

15 b) reacting a compound of formula IV:




(IV)

20

wherein R^1 is hydrogen and D , R^5 , R^{12} , R^{13} , R^{14} , and R^{15} are as defined above, or R^5 is H and R^1 , R^{12} , R^{13} , R^{14} , R^{15} , and D are as defined above, with the compound of formula III, or a suitable salt thereof in the presence of P_2O_5 and a high boiling tertiary amine or a suitable salt thereof, to form a compound of the general formula I, or

5

c) reacting a compound of the formula IV:



10


(IV)

wherein R^1 is hydrogen and D , R^5 , R^{12} , R^{13} , R^{14} and R^{15} are as defined above or R^5 is H and R^1 , R^{12} , R^{13} , R^{14} , R^{15} , and D are as defined above, with a compound of the formula III, or a suitable salt thereof in the presence of titanium tetrachloride and a solvent, or a mixture of toluene and anisole, to form a compound of the general formula I, or

15

d) reacting a compound of formula V

20



(V)

wherein R^1 , R^{12} , R^{13} , R^{14} and R^{15} are as defined above, with a compound of formula VI




5

wherein R^3 is as defined above, to form a compound of the general formula I, wherein D is SO_2 , R^2 is H, and R^4 and R^5 together form a bond, or

e) reacting a compound of the formula V

10



(V)

15

wherein R^1 , R^{12} , R^{13} , R^{14} and R^{15} are as defined above, with a compound of formula VII




20

wherein R^3 is as defined above, to form a compound of the general formula I, wherein D is SO_2 , R^2 is H, and R^4 and R^5 together form a bond, or

f) reacting a compound of the formula V


25

100



(V)

5 wherein R^1 , R^{12} , R^{13} , R^{14} and R^{15} are defined as above, with a compound of formula VIII




(VIII)

10

wherein Y is NH or S , or a suitable salt thereof, to form a compound of the general formula I, wherein D is SO_2 , R^4 and R^5 together form a bond, and R^2 and R^3 are H , or

15 g) reacting a compound of the formula V



(V)

20

101

wherein R^1 , R^{12} , R^{13} , R^{14} and R^{15} are as defined above, with a compound of formula IX




5

wherein R^3 is as defined above, to form a compound of the general formula I, wherein D is SO_2 , R^2 is H, and R^4 and R^5 together form a bond, or

h) reacting in the presence of a base a compound of formula X


10




or a suitable salt thereof, wherein R^{11} is R^1 or $EtOC(=O)$, wherein R^1 , R^{12} , R^{13} , R^{14} and R^{15} are as defined above, with a compound of formula IX



wherein R^3 is as defined above, to form an adduct which may have either of the two
20 structures XI or XII or be a mixture of the two



102




(XII)

5


either of which by ring-closure, e.g. by treatment with phosgene in a suitable solvent, forms a compound of the general formula I, if R^{11} is R^1 , wherein D is SO_2 , R^2 is H, and R^4 and R^5 together form a bond, and a compound of the general formula XIII if R^{11} is

10 $EtOC(=O)$;



(XIII)

15 and hydrolyzing and subsequently decarboxylating a compound of the general formula XIII




(XIII)

103

e.g. by heating the compound in aqueous base and subsequently neutralizing with an acid, to form a compound of the general formula I, wherein D is SO₂, R¹ and R² are H, and R⁴ and R⁵ together form a bond, or


j) reacting a compound of formula (XIV)

10




(XIV)

wherein R¹², R¹³, R¹⁴ and R¹⁵ are as defined above with thiocarbonyldiimidazole in a suitable solvent, to form a compound of formula (XV)



(XV)

20 which by treatment with an amine of formula III




(III)

104

forms a compound of the general formula I, wherein D is SO₂, R¹ is H, R⁴ and R⁵ together form a bond,

5

24. A compound of the general formula I



(I)

10

wherein

R¹ and R⁵ independently can be hydrogen; hydroxy; C₁₋₆-alkoxy; C₃₋₆-cycloalkyl optionally
 15 mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₂₋₆-
 alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen and R⁴ is
 hydrogen; or

R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and
 20 3 of formula I and R¹ is as defined above; or

R⁴ together with R¹ represent one of the bonds in a double bond between the atoms 3 and
 4 of formula I and R⁵ is as defined above;

25 D represents -S(=O)₂- or -S(=O)-;

R² is hydrogen; hydroxy; C₁₋₆-alkoxy; C₃₋₆-cycloalkyl optionally mono- or polysubstituted

with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₂₋₆- alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen;

R³ is R⁸; -OR⁸; -C(=X)R⁸; -NR⁸R⁹; or bicycloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl optionally mono- or polysubstituted with halogen, hydroxy, C₁₋₆-alkoxy, aryloxy, arylalkoxy, nitro, amino, C₁₋₆-monoalkyl- or dialkylamino, cyano, oxo, acyl, or C₁₋₆-alkoxycarbonyl; or aryl substituted with C₁₋₆-alkyl;

wherein R⁸ is hydrogen; C₃₋₆-cycloalkyl or (C₃₋₆-cycloalkyl)C₁₋₆-alkyl, C₃₋₆-cycloalkyl optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; a 3-6 membered saturated ring system comprising one or more nitrogen-, oxygen- or sulfur atoms, or straight or branched C₁₋₁₂-alkyl optionally mono- or polysubstituted with halogen, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkylthio, aryl, aryloxy, arylalkoxy, nitro, amino, C₁₋₆- monoalkyl- or dialkylamino, cyano, oxo, formyl, acyl, carboxy, C₁₋₆-alkoxycarbonyl or carbamoyl;

15

X is O or S;

R⁹ is hydrogen; C₁₋₆-alkyl; C₂₋₆-alkenyl; C₃₋₆-cycloalkyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; or


20

R⁸ and R⁹ together with the nitrogen atom form a 3-12 membered mono- or bicyclic system, in which one or more of the carbon atoms may be exchanged with nitrogen, oxygen or sulfur, each of these ring systems optionally being mono- or polysubstituted with halogen, C₁₋₆-alkyl, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, nitro, amino, cyano, trifluoromethyl, C₁₋₆-monoalkyl- or dialkylamino, oxo; or

25

R³ is

106



wherein n,m,p independently can be 0,1,2,3 and R¹⁰ is hydrogen; hydroxy; C₁₋₆-alkoxy; C₃₋₆-cycloalkyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen; or

R² and R³ together with the nitrogen atom forms a 3-12 membered mono- or bicyclic system, in which one or more of the carbon atoms may be exchanged with nitrogen, oxygen or sulfur, each of these ring systems optionally being mono- or polysubstituted with halogen, C₁₋₆-alkyl, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, nitro, amino, cyano, trifluoromethyl, C₁₋₆-monoalkyl- or dialkylamino, or oxo;

R¹², R¹³, R¹⁴, R¹⁵ independently are hydrogen; halogen; C₁₋₆-alkyl; hydroxy; C₁₋₆-alkoxy; C₁₋₆-alkoxy-C₁₋₆-alkyl; nitro; amino; cyano; perhalomethyl; C₁₋₆-monoalkyl- or dialkylamino; sulfamoyl; C₁₋₆-alkylthio; C₁₋₆-alkylsulfonyl; C₁₋₆-alkylsulfinyl; C₁₋₆-alkylcarbonylamino; arylthio, arylsulfinyl, arylsulfonyl, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; C₁₋₆-alkoxycarbonyl; carbamyl; C₁₋₆-monoalkyl- or dialkylaminocarbonyl; C₁₋₆-monoalkyl - or dialkylaminothiocarbonyl; ureido; C₁₋₆-monoalkyl- or dialkylaminocarbonylamino, thioureido; C₁₋₆-monoalkyl- or dialkylaminothiocarbonylamino; C₁₋₆-monoalkyl- or dialkylaminosulfonyl; carboxy; acyl; aryl, arylalkyl, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl;

or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form;

provided that the following compounds are not included:

- 3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-isobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-(2-ethylhexylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 5 3-cyclopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-cyclohexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-chloro-3-(1,2,2-trimethylpropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-chloro-3-(1,2-dimethylpropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-chloro-3-(1-methylpropylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 10 7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-chloro-3-cyclopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 7-chloro-3-cyclohexylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-chloro-3-cyclopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 15 6,7-dichloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 6,7-dichloro-3-cyclopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-isobutylamino-7-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-cyclopentylamino-7-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-cyclohexylamino-6-trifluoromethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 20 3-(N-cyclohexyl-N-methylamino)-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-cyclohexylamino-4-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
- 3-cyclohexylamino-2-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide.

25 25. Any novel feature or combination of features as described herein.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00266

A. CLASSIFICATION OF SUBJECT MATTER		
IPC6: C07D 285/24, C07D 417/04, C07D 417/12, C07D 453/02, C07D 453/06, A61K 31/54 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: C07D, A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
CA, WPI		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ARZNEIM-FORSCH./DRUG RES., Volume 31(I), No 2, 1981, H. Wollweber et al, "3-Amino-2H-1,2, 4-benzothiadiazin-1,1-dioxide mit antihypertensiver und potentieller diabetogener Wirkung" page 279 - page 288 --	1-17,19,20, 22-25
X	JOURNAL OF MEDICINAL CHEMISTRY, Volume 11, 1968, Timothy H. Cronin et al, "Some New 3-Amino-2H-1,2, 4-benzothiadiazine 1,1-Dioxides" page 136 - page 138 --	1-17,19,20, 22-25
X	IL FARMACO - ED. SC., Volume 29, No 6, 1974, L. Raffa et al, "Azione cardiovascolare di derivati dell' 1,2,4-benzotiadiazin-1,1-diossido" page 411 - page 423 --	1-17,19,20, 22-25
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
25 Sept 1997		26 -09- 1997
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Gerd Strandell Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00266

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FARMACO ED. SCIENTIFICA, Volume 20, 1965, L. Raffa et al, "Azione cardiovascolare di derivati del 1,2,4-benzotiadiazin-1,1-diossido - Nota II" page 647 - page 661 --	1-17,19,20, 22-25
X	IL FARMACO - ED. SC., Volume XVII, No 12, 1962, E. Grana et al, "Azione cardiovascolare di derivati del 1,2,4-benzotiadiazin-1,1,-diossido" page 974 - page 987 --	1-17,19,20, 22-25
X	US 3269906 A (JOHN GORDON TOPLISS ET AL), 30 August 1966 (30.08.66) --	1-17,19,20, 22-25
X	SE 402773 B (DAINIPPON PHARMACEUTICAL CO. LTD.), 17 July 1978 (17.07.78) --	1-17,19,20, 22-25
X	J.MED.CHEM., Volume 36, 1993, Bernard Pirotte et al, "3-(Alkylamino)-4H-pyrido 4,3-e -1,2, 4-thiadiazine 1,1-Dioxides as Powerful Inhibitors of Insulin Release from Rat Pancreatic B-Cells: A New Class of Potassium Channel Openers?", page 3211 - page 3213, Figure 1, no 6, compound 25, BPDZ 49 --	1-17,19,20, 22-25
X	ACTA CHEMICA SCANDINAVICA, Volume 27, No 7, 1973, Hans Jorgen Petersen, "Synthesis of 3-Amino- and 3-Substituted Amino-2H-1,2,4-benzothiadiazine 1, 1-Dioxides" page 2655 - page 2660 --	1-17,19,20, 22-25
X	DE 1470316 A (SCHERING AG), 24 April 1969 (24.04.69), claims 1-4,30,31,38,39 -- -----	1-10,23-25

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK97/00266

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18, 21
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1.(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

01/09/97

International application No.
PCT/DK 97/00266

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3269906 A	30/08/66	NONE	
SE 402773 B	17/07/78	SE 7604521 A	21/10/77
DE 1470316 A	24/04/69	NONE	

THIS PAGE BLANK (USPTO)